



## ***Modular Program Report***

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at [info@mini-sentinel.org](mailto:info@mini-sentinel.org).

**Overview**

**Request Description** FDA requested execution of Modular Program #2 (MP2), version 3.1, to investigate use of several antiepileptic drugs (AEDs): acetazolamide, carbamazepine, clobazam, clonazepam, diazepam, ethosuxamide, ezogabine, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, tiagabine, topiramate, valproic acid, vigabatrin, and zonisamide. This involved one run of MP2. The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of January 1, 2004 to December 31, 2012. The request was distributed to 18 Data Partners on April 23, 2012. **This report presents incidence data for AEDs incident to the drug of interest only.** Incidence with respect to all listed AEDs is presented in a separate report.

Results provide counts of prevalent and incident users of the AEDs listed above, new starts (incident use only), dispensings, total days supplied, eligible members, and member-days. Total days supplied are from the Mini-Sentinel Common Data Model (MSCDM) outpatient pharmacy table for records identified using valid NDCs (for oral forms). A new start was defined as a 183-day washout period of no prior use of the specified drug product.

**Request ID** msy4\_mpr28\_v1 - Report 1 of 2

**Table of Contents**

<b><u>Specifications</u></b>	Program parameter inputs and scenarios.
<b><u>Glossary</u></b>	List of terms found in this report and their definitions.
<b><u>Table 1a</u></b>	Table displaying the number of prevalent AED users, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product - January 1, 2004 - December 31, 2012.
<b><u>Table 1b</u></b>	Table displaying the number of incident AED users, new starts, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product - January 1, 2004 - December 31, 2012.
<b><u>Table 2a</u></b>	Table displaying the number of prevalent AED users, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and age group - January 1, 2004 - December 31, 2012.
<b><u>Table 2b</u></b>	Table displaying the number of incident AED users, new starts, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and age group - January 1, 2004 - December 31, 2012.
<b><u>Table 3a</u></b>	Table displaying the number of prevalent AED users, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and sex - January 1, 2004 - December 31, 2012.
<b><u>Table 3b</u></b>	Table displaying the number of incident AED users, new starts, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and sex - January 1, 2004 - December 31, 2012.
<b><u>Table 4a</u></b>	Table displaying the number of prevalent AED users, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and year - January 1, 2004 - December 31, 2012.
<b><u>Table 4b</u></b>	Table displaying the number of incident AED users, new starts, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and year - January 1, 2004 - December 31, 2012.
<b>Notes:</b>	Please contact the Mini-Sentinel Operations Center (MSOC_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.

**MSY4\_MPR28\_V1 Specifications #1**

Modular Program #2, version 3.1, was used to investigate use of several antiepileptic drugs (AEDs). The query period was from January 1, 2004 to December 31, 2012, and the enrollment gap was set at 45 days. Age groups were split as follows: 0-<2, 2-<5, 5-<10, 10-<17, 17-<40, 40-<65, and 65+ years. In total, 25 different scenarios are examined in this request with differing exposures of interest. See below for a description of each of these scenarios.

<b>Drug/Exposure Criteria</b>				
<b>Scenario</b>	<b>Incident exposure</b>	<b>Incident w/ respect to (incidence criteria):</b>	<b>Washout (days)</b>	<b>Incidence Type*</b>
1	Acetazolamide	Acetazolamide	183	MULT
2	Carbamazepine	Carbamazepine	183	MULT
3	Clobazam	Clobazam	183	MULT
4	Clonazepam	Clonazepam	183	MULT
5	Diazepam	Diazepam	183	MULT
6	Ethosuxamide	Ethosuxamide	183	MULT
7	Ezogabine	Ezogabine	183	MULT
8	Felbamate	Felbamate	183	MULT
9	Gabapentin	Gabapentin	183	MULT
10	Lacosamide	Lacosamide	183	MULT
11	Lamotrigine	Lamotrigine	183	MULT
12	Levetiracetam	Levetiracetam	183	MULT
13	Lorazepam	Lorazepam	183	MULT
14	Mephenytoin	Mephenytoin	183	MULT
15	Oxcarbazepine	Oxcarbazepine	183	MULT
16	Phenobarbital	Phenobarbital	183	MULT
17	Phenytoin, phenytoin sodium	Phenytoin, phenytoin sodium	183	MULT
18	Pregabalin	Pregabalin	183	MULT
19	Primidone	Primidone	183	MULT
20	Rufinamide	Rufinamide	183	MULT
21	Tiagabine	Tiagabine	183	MULT
22	Topiramate	Topiramate	183	MULT
23	Valproic acid	Valproic acid	183	MULT
24	Vigabatrin	Vigabatrin	183	MULT
25	Zonisamide	Zonisamide	183	MULT

\*A "MULT" incidence type for the exposure will consider all incident exposures (dispensings) for a member during the query period.

### Glossary of Terms in Modular Program 2\*

**Eligible Members (incidence-based cohort)** - Number of members eligible for incident exposure (defined by the washout period) with specified coverage during the query period.

**Eligible Members (prevalence-based cohort)** - Number of members with at least one day of specified coverage during the query period.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.

**Incidence Type (drug/exposure)** - Minimum incidence type will consider the first dispensing in the query period as a new start as long as it is the first dispensing in the user's entire available history. Multiple incidence type will use the washout period to establish incidence, however Multiple will consider all qualifying incident dispensings as new starts.

**Member-Days (incidence-based cohort)** - Sum of all days of enrollment with specified coverage in the query period preceded by an exposure washout period.

**Member-Days (prevalence-based cohort)** - Sum of all days members are enrolled with specified coverage during the query period.

**New Starts**- Number of incident exposures during the query period. User must have no prior exposures in the washout period. For a minimum incidence type, an individual may have no more than one new start. For a multiple incidence type, an individual may have more than one new start.

**New Users** - Number of members with incident exposure during the query period. Member must have no evidence of exposure (s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.

**Query Period** - period in which the modular program looks for exposures of interest.

**Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous specified coverage.

\*all terms may not be used in this report

**Table 1a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
Acetazolamide	228,974	607,152	16,550,557	121,289,091	105,073,234,753	188.8	72.3	2.7	27.3
Carbamazepine	313,830	3,724,009	139,949,159	121,289,091	105,073,234,753	258.7	445.9	11.9	37.6
Clobazam	691	2,407	78,346	121,289,091	105,073,234,753	0.6	113.4	3.5	32.5
Clonazepam	1,965,809	15,632,574	496,249,684	121,289,091	105,073,234,753	1,620.8	252.4	8.0	31.7
Diazepam	2,908,242	9,946,947	219,092,261	121,289,091	105,073,234,753	2,397.8	75.3	3.4	22.0
Ethosuxamide	8,472	104,818	3,722,767	121,289,091	105,073,234,753	7.0	439.4	12.4	35.5
Ezogabine	58	132	4,057	121,289,091	105,073,234,753	0.0	69.9	2.3	30.7
Felbamate	3,233	59,632	2,072,301	121,289,091	105,073,234,753	2.7	641.0	18.4	34.8
Gabapentin	3,090,205	21,238,425	780,800,914	121,289,091	105,073,234,753	2,547.8	252.7	6.9	36.8
Lacosamide	14,747	107,891	3,529,848	121,289,091	105,073,234,753	12.2	239.4	7.3	32.7
Lamotrigine	726,430	8,003,136	284,699,943	121,289,091	105,073,234,753	598.9	391.9	11.0	35.6
Levetiracetam	343,529	3,436,123	121,242,966	121,289,091	105,073,234,753	283.2	352.9	10.0	35.3
Lorazepam	3,386,329	17,535,138	450,388,602	121,289,091	105,073,234,753	2,791.9	133.0	5.2	25.7
Mephenytoin	1	1	30	121,289,091	105,073,234,753	0.0	30.0	1.0	30.0
Oxcarbazepine	262,237	2,503,564	84,232,724	121,289,091	105,073,234,753	216.2	321.2	9.5	33.6
Phenobarbital	78,234	936,353	34,927,655	121,289,091	105,073,234,753	64.5	446.5	12.0	37.3
Phenytoin, Phenytoin sodium	324,143	4,580,272	170,540,569	121,289,091	105,073,234,753	267.2	526.1	14.1	37.2
Pregabalin	799,223	4,888,249	163,423,824	121,289,091	105,073,234,753	658.9	204.5	6.1	33.4
Primidone	108,304	1,171,103	47,163,175	121,289,091	105,073,234,753	89.3	435.5	10.8	40.3
Rufinamide	2,055	19,123	615,530	121,289,091	105,073,234,753	1.7	299.5	9.3	32.2
Tiagabine	38,076	241,581	7,743,690	121,289,091	105,073,234,753	31.4	203.4	6.3	32.1
Topiramate	931,477	7,214,904	254,747,683	121,289,091	105,073,234,753	768.0	273.5	7.7	35.3
Valproic acid	50,363	339,723	13,795,796	121,289,091	105,073,234,753	41.5	273.9	6.7	40.6
Vigabatrin	437	4,046	123,219	121,289,091	105,073,234,753	0.4	282.0	9.3	30.5
Zonisamide	93,285	789,167	27,026,070	121,289,091	105,073,234,753	76.9	289.7	8.5	34.2

**Table 1b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
Acetazolamide	182,002	201,356	356,601	8,332,483	99,389,815	84,342,275,560	183.1	45.8	2.0	23.4
Carbamazepine	143,070	166,314	863,179	34,115,080	99,301,646	84,239,806,342	144.1	238.5	6.0	39.5
Clobazam	572	575	1,935	64,198	99,401,283	84,392,133,944	0.6	112.2	3.4	33.2
Clonazepam	1,201,118	1,463,214	6,742,188	209,364,978	99,032,692	83,638,440,296	1,212.8	174.3	5.6	31.1
Diazepam	2,238,223	2,695,895	5,570,733	103,306,609	99,223,702	83,632,757,792	2,255.7	46.2	2.5	18.5
Ethosuxamide	4,010	4,518	41,293	1,454,587	99,398,997	84,388,016,307	4.0	362.7	10.3	35.2
Ezogabine	48	48	104	3,249	99,401,320	84,392,201,307	0.0	67.7	2.2	31.2
Felbamate	989	1,106	13,136	460,705	99,399,803	84,390,229,087	1.0	465.8	13.3	35.1
Gabapentin	2,040,036	2,387,020	10,524,577	391,850,539	98,921,367	83,318,500,976	2,062.3	192.1	5.2	37.2
Lacosamide	10,423	10,728	78,389	2,573,140	99,399,387	84,388,331,610	10.5	246.9	7.5	32.8
Lamotrigine	373,744	414,965	3,375,038	120,904,882	99,208,535	84,087,869,867	376.7	323.5	9.0	35.8
Levetiracetam	196,792	212,451	1,631,658	58,226,014	99,321,522	84,259,996,651	198.1	295.9	8.3	35.7
Lorazepam	2,487,617	3,154,295	9,316,540	215,697,120	99,064,723	83,309,128,346	2,511.1	86.7	3.7	23.2
Mephenytoin	1	1	1	30	99,401,325	84,392,203,673	0.0	30.0	1.0	30.0
Oxcarbazepine	143,294	157,519	1,037,010	34,746,246	99,346,873	84,290,383,777	144.2	242.5	7.2	33.5
Phenobarbital	38,796	44,007	196,152	7,235,465	99,379,054	84,353,378,582	39.0	186.5	5.1	36.9
Phenytoin, phenytoin sodium	119,781	135,165	870,068	33,728,567	99,272,809	84,223,230,237	120.7	281.6	7.3	38.8
Pregabalin	484,894	529,743	2,450,439	81,504,151	99,293,095	84,156,589,013	488.3	168.1	5.1	33.3
Primidone	58,847	67,772	415,595	17,396,020	99,370,624	84,339,488,081	59.2	295.6	7.1	41.9
Rufinamide	1,514	1,563	14,347	466,251	99,401,054	84,391,512,327	1.5	308.0	9.5	32.5
Tiagabine	22,125	23,370	95,847	2,967,058	99,396,729	84,380,248,778	22.3	134.1	4.3	31.0
Topiramate	557,718	629,758	3,329,282	118,032,352	99,237,388	84,062,386,557	562.0	211.6	6.0	35.5
Valproic acid	34,013	40,957	187,634	8,453,130	99,395,396	84,373,462,626	34.2	248.5	5.5	45.1
Vigabatrin	309	316	2,963	90,369	99,401,253	84,392,063,857	0.3	292.5	9.6	30.5
Zonisamide	54,187	58,439	344,464	11,648,686	99,384,111	84,358,897,244	54.5	215.0	6.4	33.8

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>									
0-2 years	138	380	9,978	5,668,911	2,189,289,230	2.4	72.3	2.8	26.3
2-5 years	227	672	17,573	7,214,012	3,636,254,820	3.1	77.4	3.0	26.2
5-10 years	1,158	3,554	95,997	10,305,203	6,396,469,967	11.2	82.9	3.1	27.0
10-17 years	6,537	16,252	413,896	13,615,115	9,624,000,886	48.0	63.3	2.5	25.5
17-40 years	53,852	130,894	3,440,023	46,832,594	31,714,782,644	115.0	63.9	2.4	26.3
40-65 years	98,106	252,522	6,855,826	42,577,937	37,202,795,947	230.4	69.9	2.6	27.1
65+ years	71,841	202,878	5,717,264	14,742,004	14,218,632,910	487.3	79.6	2.8	28.2
<b>Carbamazepine</b>									
0-2 years	646	3,247	107,725	5,668,911	2,189,289,230	11.4	166.8	5.0	33.2
2-5 years	2,053	15,125	509,727	7,214,012	3,636,254,820	28.5	248.3	7.4	33.7
5-10 years	5,977	61,415	2,081,167	10,305,203	6,396,469,967	58.0	348.2	10.3	33.9
10-17 years	13,973	157,591	5,411,251	13,615,115	9,624,000,886	102.6	387.3	11.3	34.3
17-40 years	88,163	933,065	32,853,793	46,832,594	31,714,782,644	188.3	372.6	10.6	35.2
40-65 years	148,709	1,794,761	68,255,053	42,577,937	37,202,795,947	349.3	459.0	12.1	38.0
65+ years	71,899	758,805	30,730,443	14,742,004	14,218,632,910	487.7	427.4	10.6	40.5
<b>Clobazam</b>									
0-2 years	28	87	2,690	5,668,911	2,189,289,230	0.5	96.1	3.1	30.9
2-5 years	90	363	11,281	7,214,012	3,636,254,820	1.2	125.3	4.0	31.1
5-10 years	138	487	15,937	10,305,203	6,396,469,967	1.3	115.5	3.5	32.7
10-17 years	199	689	22,692	13,615,115	9,624,000,886	1.5	114.0	3.5	32.9
17-40 years	189	608	19,533	46,832,594	31,714,782,644	0.4	103.3	3.2	32.1
40-65 years	57	151	5,458	42,577,937	37,202,795,947	0.1	95.8	2.6	36.1
65+ years	9	22	755	14,742,004	14,218,632,910	0.1	83.9	2.4	34.3

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Clonazepam</b>									
0-2 years	1,285	5,381	156,456	5,668,911	2,189,289,230	22.7	121.8	4.2	29.1
2-5 years	2,503	15,060	450,241	7,214,012	3,636,254,820	34.7	179.9	6.0	29.9
5-10 years	6,274	38,542	1,192,569	10,305,203	6,396,469,967	60.9	190.1	6.1	30.9
10-17 years	27,978	130,558	3,886,361	13,615,115	9,624,000,886	205.5	138.9	4.7	29.8
17-40 years	680,924	3,794,605	106,691,348	46,832,594	31,714,782,644	1,454.0	156.7	5.6	28.1
40-65 years	1,021,937	9,089,306	289,844,844	42,577,937	37,202,795,947	2,400.2	283.6	8.9	31.9
65+ years	292,944	2,559,122	94,027,865	14,742,004	14,218,632,910	1,987.1	321.0	8.7	36.7
<b>Diazepam</b>									
0-2 years	1,560	3,244	65,020	5,668,911	2,189,289,230	27.5	41.7	2.1	20.0
2-5 years	8,151	14,092	184,304	7,214,012	3,636,254,820	113.0	22.6	1.7	13.1
5-10 years	26,865	44,567	470,117	10,305,203	6,396,469,967	260.7	17.5	1.7	10.5
10-17 years	64,377	98,964	1,072,470	13,615,115	9,624,000,886	472.8	16.7	1.5	10.8
17-40 years	846,816	1,878,631	30,316,352	46,832,594	31,714,782,644	1,808.2	35.8	2.2	16.1
40-65 years	1,551,188	5,906,159	131,375,314	42,577,937	37,202,795,947	3,643.2	84.7	3.8	22.2
65+ years	461,585	2,001,290	55,608,684	14,742,004	14,218,632,910	3,131.1	120.5	4.3	27.8
<b>Ethosuxamide</b>									
0-2 years	29	115	3,603	5,668,911	2,189,289,230	0.5	124.2	4.0	31.3
2-5 years	640	3,881	122,467	7,214,012	3,636,254,820	8.9	191.4	6.1	31.6
5-10 years	3,677	34,484	1,146,889	10,305,203	6,396,469,967	35.7	311.9	9.4	33.3
10-17 years	3,055	31,148	1,079,432	13,615,115	9,624,000,886	22.4	353.3	10.2	34.7
17-40 years	1,388	15,605	573,229	46,832,594	31,714,782,644	3.0	413.0	11.2	36.7
40-65 years	976	16,713	670,504	42,577,937	37,202,795,947	2.3	687.0	17.1	40.1
65+ years	196	2,872	126,643	14,742,004	14,218,632,910	1.3	646.1	14.7	44.1



**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Ezogabine</i></b>									
0-2 years	0	0	0	5,668,911	2,189,289,230	0.0	---	---	---
2-5 years	0	0	0	7,214,012	3,636,254,820	0.0	---	---	---
5-10 years	1	1	30	10,305,203	6,396,469,967	0.0	30.0	1.0	30.0
10-17 years	4	7	213	13,615,115	9,624,000,886	0.0	53.3	1.8	30.4
17-40 years	29	60	1,877	46,832,594	31,714,782,644	0.1	64.7	2.1	31.3
40-65 years	22	57	1,727	42,577,937	37,202,795,947	0.1	78.5	2.6	30.3
65+ years	3	7	210	14,742,004	14,218,632,910	0.0	70.0	2.3	30.0
<b><i>Felbamate</i></b>									
0-2 years	73	389	11,221	5,668,911	2,189,289,230	1.3	153.7	5.3	28.8
2-5 years	186	1,737	56,358	7,214,012	3,636,254,820	2.6	303.0	9.3	32.4
5-10 years	423	5,301	175,425	10,305,203	6,396,469,967	4.1	414.7	12.5	33.1
10-17 years	677	10,254	343,012	13,615,115	9,624,000,886	5.0	506.7	15.1	33.5
17-40 years	1,341	25,446	863,580	46,832,594	31,714,782,644	2.9	644.0	19.0	33.9
40-65 years	871	14,589	545,262	42,577,937	37,202,795,947	2.0	626.0	16.7	37.4
65+ years	144	1,916	77,443	14,742,004	14,218,632,910	1.0	537.8	13.3	40.4
<b><i>Gabapentin</i></b>									
0-2 years	345	1,170	35,275	5,668,911	2,189,289,230	6.1	102.2	3.4	30.1
2-5 years	1,244	6,152	184,776	7,214,012	3,636,254,820	17.2	148.5	4.9	30.0
5-10 years	3,930	21,243	669,716	10,305,203	6,396,469,967	38.1	170.4	5.4	31.5
10-17 years	19,807	91,386	2,938,997	13,615,115	9,624,000,886	145.5	148.4	4.6	32.2
17-40 years	455,963	2,020,717	64,302,770	46,832,594	31,714,782,644	973.6	141.0	4.4	31.8
40-65 years	1,574,439	10,532,255	376,881,850	42,577,937	37,202,795,947	3,697.8	239.4	6.7	35.8
65+ years	1,112,836	8,565,502	335,787,530	14,742,004	14,218,632,910	7,548.7	301.7	7.7	39.2

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Lacosamide</i></b>									
0-2 years	41	164	5,301	5,668,911	2,189,289,230	0.7	129.3	4.0	32.3
2-5 years	118	612	18,260	7,214,012	3,636,254,820	1.6	154.7	5.2	29.8
5-10 years	348	2,309	74,224	10,305,203	6,396,469,967	3.4	213.3	6.6	32.1
10-17 years	869	6,758	217,339	13,615,115	9,624,000,886	6.4	250.1	7.8	32.2
17-40 years	5,744	42,256	1,361,821	46,832,594	31,714,782,644	12.3	237.1	7.4	32.2
40-65 years	6,445	46,406	1,547,963	42,577,937	37,202,795,947	15.1	240.2	7.2	33.4
65+ years	1,596	9,386	304,940	14,742,004	14,218,632,910	10.8	191.1	5.9	32.5
<b><i>Lamotrigine</i></b>									
0-2 years	482	2,523	80,767	5,668,911	2,189,289,230	8.5	167.6	5.2	32.0
2-5 years	2,551	21,265	698,624	7,214,012	3,636,254,820	35.4	273.9	8.3	32.9
5-10 years	12,077	127,012	4,182,160	10,305,203	6,396,469,967	117.2	346.3	10.5	32.9
10-17 years	50,342	493,306	16,386,800	13,615,115	9,624,000,886	369.8	325.5	9.8	33.2
17-40 years	333,510	3,056,434	103,945,039	46,832,594	31,714,782,644	712.1	311.7	9.2	34.0
40-65 years	319,923	3,757,287	137,997,262	42,577,937	37,202,795,947	751.4	431.3	11.7	36.7
65+ years	48,427	545,309	21,409,291	14,742,004	14,218,632,910	328.5	442.1	11.3	39.3
<b><i>Levetiracetam</i></b>									
0-2 years	5,311	30,927	992,418	5,668,911	2,189,289,230	93.7	186.9	5.8	32.1
2-5 years	8,897	77,149	2,499,345	7,214,012	3,636,254,820	123.3	280.9	8.7	32.4
5-10 years	13,229	139,520	4,584,859	10,305,203	6,396,469,967	128.4	346.6	10.5	32.9
10-17 years	19,680	214,207	7,164,587	13,615,115	9,624,000,886	144.5	364.1	10.9	33.4
17-40 years	84,644	807,223	27,612,338	46,832,594	31,714,782,644	180.7	326.2	9.5	34.2
40-65 years	134,500	1,290,441	46,178,482	42,577,937	37,202,795,947	315.9	343.3	9.6	35.8
65+ years	96,300	876,656	32,210,937	14,742,004	14,218,632,910	653.2	334.5	9.1	36.7

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lorazepam</b>									
0-2 years	1,535	2,674	53,029	5,668,911	2,189,289,230	27.1	34.5	1.7	19.8
2-5 years	2,351	4,954	95,137	7,214,012	3,636,254,820	32.6	40.5	2.1	19.2
5-10 years	7,481	15,008	262,801	10,305,203	6,396,469,967	72.6	35.1	2.0	17.5
10-17 years	41,097	84,633	1,477,201	13,615,115	9,624,000,886	301.8	35.9	2.1	17.5
17-40 years	902,618	2,783,303	57,417,336	46,832,594	31,714,782,644	1,927.3	63.6	3.1	20.6
40-65 years	1,698,439	9,279,633	234,065,739	42,577,937	37,202,795,947	3,989.0	137.8	5.5	25.2
65+ years	816,190	5,364,933	157,017,359	14,742,004	14,218,632,910	5,536.5	192.4	6.6	29.3
<b>Mephenytoin</b>									
0-2 years	0	0	0	5,668,911	2,189,289,230	0.0	---	---	---
2-5 years	0	0	0	7,214,012	3,636,254,820	0.0	---	---	---
5-10 years	0	0	0	10,305,203	6,396,469,967	0.0	---	---	---
10-17 years	0	0	0	13,615,115	9,624,000,886	0.0	---	---	---
17-40 years	0	0	0	46,832,594	31,714,782,644	0.0	---	---	---
40-65 years	1	1	30	42,577,937	37,202,795,947	0.0	30.0	1.0	30.0
65+ years	0	0	0	14,742,004	14,218,632,910	0.0	---	---	---
<b>Oxcarbazepine</b>									
0-2 years	1,950	10,019	319,610	5,668,911	2,189,289,230	34.4	163.9	5.1	31.9
2-5 years	5,672	44,544	1,399,812	7,214,012	3,636,254,820	78.6	246.8	7.9	31.4
5-10 years	18,001	173,709	5,455,934	10,305,203	6,396,469,967	174.7	303.1	9.6	31.4
10-17 years	39,828	384,607	12,457,391	13,615,115	9,624,000,886	292.5	312.8	9.7	32.4
17-40 years	95,741	763,818	24,954,022	46,832,594	31,714,782,644	204.4	260.6	8.0	32.7
40-65 years	94,690	894,290	31,095,791	42,577,937	37,202,795,947	222.4	328.4	9.4	34.8
65+ years	25,493	232,577	8,550,164	14,742,004	14,218,632,910	172.9	335.4	9.1	36.8

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Phenobarbital</i></b>									
0-2 years	6,600	31,124	969,500	5,668,911	2,189,289,230	116.4	146.9	4.7	31.1
2-5 years	2,307	21,308	692,054	7,214,012	3,636,254,820	32.0	300.0	9.2	32.5
5-10 years	1,729	23,529	767,827	10,305,203	6,396,469,967	16.8	444.1	13.6	32.6
10-17 years	1,992	32,756	1,055,647	13,615,115	9,624,000,886	14.6	529.9	16.4	32.2
17-40 years	13,488	133,167	4,447,457	46,832,594	31,714,782,644	28.8	329.7	9.9	33.4
40-65 years	33,420	463,425	17,399,176	42,577,937	37,202,795,947	78.5	520.6	13.9	37.5
65+ years	23,720	231,044	9,595,994	14,742,004	14,218,632,910	160.9	404.6	9.7	41.5
<b><i>Phenytoin, phenytoin</i></b>									
0-2 years	601	1,774	55,439	5,668,911	2,189,289,230	10.6	92.2	3.0	31.3
2-5 years	856	3,809	118,205	7,214,012	3,636,254,820	11.9	138.1	4.4	31.0
5-10 years	1,513	9,982	324,448	10,305,203	6,396,469,967	14.7	214.4	6.6	32.5
10-17 years	4,080	28,471	957,808	13,615,115	9,624,000,886	30.0	234.8	7.0	33.6
17-40 years	57,587	617,029	21,169,312	46,832,594	31,714,782,644	123.0	367.6	10.7	34.3
40-65 years	153,152	2,242,867	82,727,645	42,577,937	37,202,795,947	359.7	540.2	14.6	36.9
65+ years	121,422	1,676,340	65,187,712	14,742,004	14,218,632,910	823.6	536.9	13.8	38.9
<b><i>Pregabalin</i></b>									
0-2 years	28	177	5,079	5,668,911	2,189,289,230	0.5	181.4	6.3	28.7
2-5 years	125	938	28,512	7,214,012	3,636,254,820	1.7	228.1	7.5	30.4
5-10 years	324	2,332	73,993	10,305,203	6,396,469,967	3.1	228.4	7.2	31.7
10-17 years	2,593	12,348	381,870	13,615,115	9,624,000,886	19.0	147.3	4.8	30.9
17-40 years	115,946	533,973	16,577,798	46,832,594	31,714,782,644	247.6	143.0	4.6	31.0
40-65 years	449,418	2,750,568	92,262,962	42,577,937	37,202,795,947	1,055.5	205.3	6.1	33.5
65+ years	246,459	1,587,913	54,093,610	14,742,004	14,218,632,910	1,671.8	219.5	6.4	34.1

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Primidone</b>									
0-2 years	21	101	2,719	5,668,911	2,189,289,230	0.4	129.5	4.8	26.9
2-5 years	46	409	13,549	7,214,012	3,636,254,820	0.6	294.5	8.9	33.1
5-10 years	126	1,525	49,279	10,305,203	6,396,469,967	1.2	391.1	12.1	32.3
10-17 years	424	4,321	137,494	13,615,115	9,624,000,886	3.1	324.3	10.2	31.8
17-40 years	5,919	46,789	1,575,912	46,832,594	31,714,782,644	12.6	266.2	7.9	33.7
40-65 years	38,007	396,557	15,147,043	42,577,937	37,202,795,947	89.3	398.5	10.4	38.2
65+ years	67,058	721,401	30,237,179	14,742,004	14,218,632,910	454.9	450.9	10.8	41.9
<b>Rufinamide</b>									
0-2 years	62	189	5,886	5,668,911	2,189,289,230	1.1	94.9	3.0	31.1
2-5 years	260	1,818	57,087	7,214,012	3,636,254,820	3.6	219.6	7.0	31.4
5-10 years	488	3,944	125,012	10,305,203	6,396,469,967	4.7	256.2	8.1	31.7
10-17 years	610	5,311	171,457	13,615,115	9,624,000,886	4.5	281.1	8.7	32.3
17-40 years	663	6,350	207,240	46,832,594	31,714,782,644	1.4	312.6	9.6	32.6
40-65 years	174	1,470	47,386	42,577,937	37,202,795,947	0.4	272.3	8.4	32.2
65+ years	9	41	1,462	14,742,004	14,218,632,910	0.1	162.4	4.6	35.7
<b>Tiagabine</b>									
0-2 years	14	31	820	5,668,911	2,189,289,230	0.2	58.6	2.2	26.5
2-5 years	41	272	8,040	7,214,012	3,636,254,820	0.6	196.1	6.6	29.6
5-10 years	249	1,610	50,232	10,305,203	6,396,469,967	2.4	201.7	6.5	31.2
10-17 years	1,000	7,321	232,694	13,615,115	9,624,000,886	7.3	232.7	7.3	31.8
17-40 years	11,857	62,554	1,929,712	46,832,594	31,714,782,644	25.3	162.7	5.3	30.8
40-65 years	22,530	146,894	4,774,774	42,577,937	37,202,795,947	52.9	211.9	6.5	32.5
65+ years	3,263	22,899	747,418	14,742,004	14,218,632,910	22.1	229.1	7.0	32.6

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>									
0-2 years	1,631	10,442	323,160	5,668,911	2,189,289,230	28.8	198.1	6.4	30.9
2-5 years	2,735	22,826	741,288	7,214,012	3,636,254,820	37.9	271.0	8.3	32.5
5-10 years	9,067	69,992	2,266,851	10,305,203	6,396,469,967	88.0	250.0	7.7	32.4
10-17 years	46,045	284,979	9,372,691	13,615,115	9,624,000,886	338.2	203.6	6.2	32.9
17-40 years	386,111	2,421,070	81,146,765	46,832,594	31,714,782,644	824.4	210.2	6.3	33.5
40-65 years	463,368	3,950,907	143,007,820	42,577,937	37,202,795,947	1,088.3	308.6	8.5	36.2
65+ years	60,758	454,688	17,889,108	14,742,004	14,218,632,910	412.1	294.4	7.5	39.3
<b><i>Valproic acid</i></b>									
0-2 years	8	9	270	5,668,911	2,189,289,230	0.1	33.8	1.1	30.0
2-5 years	43	128	4,618	7,214,012	3,636,254,820	0.6	107.4	3.0	36.1
5-10 years	436	1,887	72,329	10,305,203	6,396,469,967	4.2	165.9	4.3	38.3
10-17 years	2,269	9,745	373,106	13,615,115	9,624,000,886	16.7	164.4	4.3	38.3
17-40 years	16,247	73,810	2,794,961	46,832,594	31,714,782,644	34.7	172.0	4.5	37.9
40-65 years	23,201	178,361	7,243,439	42,577,937	37,202,795,947	54.5	312.2	7.7	40.6
65+ years	9,843	75,783	3,307,073	14,742,004	14,218,632,910	66.8	336.0	7.7	43.6
<b><i>Vigabatrin</i></b>									
0-2 years	183	1,082	32,998	5,668,911	2,189,289,230	3.2	180.3	5.9	30.5
2-5 years	127	891	27,309	7,214,012	3,636,254,820	1.8	215.0	7.0	30.6
5-10 years	84	871	26,402	10,305,203	6,396,469,967	0.8	314.3	10.4	30.3
10-17 years	60	571	17,435	13,615,115	9,624,000,886	0.4	290.6	9.5	30.5
17-40 years	50	515	15,419	46,832,594	31,714,782,644	0.1	308.4	10.3	29.9
40-65 years	14	115	3,626	42,577,937	37,202,795,947	0.0	259.0	8.2	31.5
65+ years	1	1	30	14,742,004	14,218,632,910	0.0	30.0	1.0	30.0

Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Zonisamide</b>									
0-2 years	641	4,011	124,224	5,668,911	2,189,289,230	11.3	193.8	6.3	31.0
2-5 years	1,304	12,327	384,798	7,214,012	3,636,254,820	18.1	295.1	9.5	31.2
5-10 years	2,609	30,436	992,226	10,305,203	6,396,469,967	25.3	380.3	11.7	32.6
10-17 years	5,810	62,297	2,032,536	13,615,115	9,624,000,886	42.7	349.8	10.7	32.6
17-40 years	33,984	250,393	8,305,086	46,832,594	31,714,782,644	72.6	244.4	7.4	33.2
40-65 years	44,620	354,117	12,292,901	42,577,937	37,202,795,947	104.8	275.5	7.9	34.7
65+ years	8,642	75,586	2,894,299	14,742,004	14,218,632,910	58.6	334.9	8.7	38.3

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>										
0-2 years	67	68	167	4,406	3,816,355	1,278,506,976	1.8	65.8	2.5	26.4
2-5 years	164	172	405	10,033	5,838,122	2,902,764,695	2.8	61.2	2.5	24.8
5-10 years	860	909	2,288	59,777	8,467,020	5,168,989,731	10.2	69.5	2.7	26.1
10-17 years	5,107	5,533	10,603	251,708	11,336,190	7,859,137,109	45.1	49.3	2.1	23.7
17-40 years	41,351	44,406	79,467	1,902,481	36,661,470	24,302,110,645	112.8	46.0	1.9	23.9
40-65 years	79,088	89,155	146,720	3,349,977	35,530,497	30,723,225,539	222.6	42.4	1.9	22.8
65+ years	56,543	61,113	112,821	2,604,390	13,110,252	12,033,508,075	431.3	46.1	2.0	23.1
<b>Carbamazepine</b>										
0-2 years	341	344	1,467	49,991	3,816,245	1,278,416,191	8.9	146.6	4.3	34.1
2-5 years	980	1,016	5,847	208,748	5,837,675	2,902,227,734	16.8	213.0	6.0	35.7
5-10 years	2,313	2,423	17,447	606,117	8,465,290	5,167,007,747	27.3	262.0	7.5	34.7
10-17 years	5,625	6,093	38,935	1,375,074	11,332,320	7,854,515,544	49.6	244.5	6.9	35.3
17-40 years	37,052	41,438	202,073	7,244,433	36,635,866	24,277,324,718	101.1	195.5	5.5	35.9
40-65 years	63,107	73,138	363,493	14,613,152	35,481,809	30,671,656,466	177.9	231.6	5.8	40.2
65+ years	34,934	41,862	193,523	8,367,997	13,091,246	12,014,626,084	266.9	239.5	5.5	43.2
<b>Clobazam</b>										
0-2 years	21	21	65	2,013	3,816,366	1,278,524,294	0.6	95.9	3.1	31.0
2-5 years	73	73	283	9,206	5,838,140	2,902,795,714	1.3	126.1	3.9	32.5
5-10 years	107	108	352	11,943	8,467,088	5,169,206,129	1.3	111.6	3.3	33.9
10-17 years	160	162	577	18,916	11,336,525	7,860,408,564	1.4	118.2	3.6	32.8
17-40 years	154	154	474	15,472	36,664,445	24,312,632,848	0.4	100.5	3.1	32.6
40-65 years	52	52	130	4,768	35,535,569	30,745,006,437	0.1	91.7	2.5	36.7
65+ years	5	5	10	420	13,114,989	12,049,526,206	0.0	84.0	2.0	42.0



**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Clonazepam</i></b>										
0-2 years	753	773	2,723	78,846	3,816,146	1,278,309,678	19.7	104.7	3.6	29.0
2-5 years	1,485	1,595	6,373	184,854	5,837,593	2,902,136,939	25.4	124.5	4.3	29.0
5-10 years	4,071	4,395	15,691	478,734	8,465,955	5,167,452,300	48.1	117.6	3.9	30.5
10-17 years	19,843	21,628	69,078	1,992,574	11,333,255	7,853,554,152	175.1	100.4	3.5	28.8
17-40 years	416,426	483,533	1,868,876	51,074,418	36,558,181	24,127,833,249	1,139.1	122.6	4.5	27.3
40-65 years	589,283	727,134	3,529,058	110,193,829	35,298,188	30,320,454,213	1,669.4	187.0	6.0	31.2
65+ years	182,324	224,156	1,078,170	39,548,042	13,049,733	11,914,676,545	1,397.1	216.9	5.9	36.7
<b><i>Diazepam</i></b>										
0-2 years	1,009	1,029	1,772	32,579	3,816,216	1,278,338,742	26.4	32.3	1.8	18.4
2-5 years	6,318	6,597	9,302	92,496	5,837,633	2,901,528,413	108.2	14.6	1.5	9.9
5-10 years	21,428	23,161	30,941	232,664	8,465,971	5,164,394,406	253.1	10.9	1.4	7.5
10-17 years	53,498	56,592	72,206	583,666	11,334,407	7,849,416,855	472.0	10.9	1.3	8.1
17-40 years	634,425	703,485	1,212,318	16,935,495	36,622,423	24,152,521,273	1,732.3	26.7	1.9	14.0
40-65 years	1,191,194	1,456,402	3,181,995	59,213,121	35,420,674	30,316,521,154	3,363.0	49.7	2.7	18.6
65+ years	353,274	448,629	990,469	24,196,154	13,069,731	11,896,023,919	2,703.0	68.5	2.8	24.4
<b><i>Ethosuxamide</i></b>										
0-2 years	19	19	61	1,817	3,816,361	1,278,522,678	0.5	95.6	3.2	29.8
2-5 years	420	427	2,471	77,802	5,838,052	2,902,678,138	7.2	185.2	5.9	31.5
5-10 years	1,890	1,999	17,097	578,706	8,466,147	5,167,929,498	22.3	306.2	9.0	33.8
10-17 years	1,152	1,273	10,395	363,532	11,335,502	7,859,088,642	10.2	315.6	9.0	35.0
17-40 years	409	498	2,716	110,059	36,663,852	24,312,012,403	1.1	269.1	6.6	40.5
40-65 years	193	247	1,642	73,610	35,534,981	30,744,349,308	0.5	381.4	8.5	44.8
65+ years	42	55	347	17,684	13,114,872	12,049,402,010	0.3	421.0	8.3	51.0

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Ezogabine</i></b>										
0-2 years	0	0	0	0	3,816,367	1,278,526,039	0.0	---	---	---
2-5 years	0	0	0	0	5,838,147	2,902,805,479	0.0	---	---	---
5-10 years	0	0	0	0	8,467,104	5,169,219,488	0.0	---	---	---
10-17 years	3	3	6	183	11,336,545	7,860,428,244	0.0	61.0	2.0	30.5
17-40 years	25	25	43	1,383	36,664,459	24,312,650,618	0.1	55.3	1.7	32.2
40-65 years	19	19	52	1,593	35,535,569	30,745,010,949	0.1	83.8	2.7	30.6
65+ years	1	1	3	90	13,114,992	12,049,526,731	0.0	90.0	3.0	30.0
<b><i>Felbamate</i></b>										
0-2 years	48	49	293	8,400	3,816,359	1,278,514,967	1.3	175.0	6.1	28.7
2-5 years	82	83	596	19,872	5,838,090	2,902,750,016	1.4	242.3	7.3	33.3
5-10 years	166	173	2,024	67,771	8,466,946	5,169,052,349	2.0	408.3	12.2	33.5
10-17 years	197	200	2,557	80,950	11,336,199	7,860,102,607	1.7	410.9	13.0	31.7
17-40 years	315	352	3,931	141,002	36,663,719	24,311,826,728	0.9	447.6	12.5	35.9
40-65 years	166	219	1,596	69,185	35,535,067	30,744,496,425	0.5	416.8	9.6	43.3
65+ years	24	30	206	7,983	13,114,900	12,049,452,236	0.2	332.6	8.6	38.8
<b><i>Gabapentin</i></b>										
0-2 years	204	206	614	18,504	3,816,314	1,278,483,710	5.3	90.7	3.0	30.1
2-5 years	867	893	3,782	113,899	5,837,981	2,902,521,430	14.9	131.4	4.4	30.1
5-10 years	2,587	2,717	10,910	343,100	8,466,546	5,168,204,676	30.6	132.6	4.2	31.4
10-17 years	14,079	14,821	50,215	1,596,549	11,334,525	7,855,629,002	124.2	113.4	3.6	31.8
17-40 years	303,446	334,593	1,094,149	34,679,614	36,615,243	24,205,696,669	828.7	114.3	3.6	31.7
40-65 years	1,014,668	1,178,615	5,020,231	181,075,247	35,276,369	30,217,694,377	2,876.3	178.5	4.9	36.1
65+ years	719,156	855,175	4,150,829	166,078,135	12,893,447	11,616,242,433	5,577.7	230.9	5.8	40.0

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Lacosamide</i></b>										
0-2 years	27	27	114	3,679	3,816,359	1,278,521,879	0.7	136.3	4.2	32.3
2-5 years	75	75	366	10,627	5,838,120	2,902,784,959	1.3	141.7	4.9	29.0
5-10 years	253	259	1,757	56,895	8,467,049	5,169,134,904	3.0	224.9	6.9	32.4
10-17 years	649	657	4,930	159,171	11,336,406	7,860,194,326	5.7	245.3	7.6	32.3
17-40 years	3,902	4,009	29,730	955,246	36,663,604	24,311,154,500	10.6	244.8	7.6	32.1
40-65 years	4,426	4,565	32,721	1,095,307	35,534,564	30,743,313,904	12.5	247.5	7.4	33.5
65+ years	1,112	1,136	6,573	218,535	13,114,742	12,049,193,438	8.5	196.5	5.9	33.2
<b><i>Lamotrigine</i></b>										
0-2 years	331	334	1,687	53,807	3,816,302	1,278,449,589	8.7	162.6	5.1	31.9
2-5 years	1,408	1,442	10,417	341,178	5,837,543	2,902,133,646	24.1	242.3	7.4	32.8
5-10 years	6,449	6,703	58,027	1,885,528	8,463,844	5,165,079,864	76.2	292.4	9.0	32.5
10-17 years	28,686	30,237	236,742	7,746,551	11,324,683	7,843,142,305	253.3	270.0	8.3	32.7
17-40 years	166,998	183,059	1,260,549	42,769,567	36,578,344	24,197,353,717	456.5	256.1	7.5	33.9
40-65 years	150,339	167,717	1,423,980	53,330,711	35,431,633	30,599,987,666	424.3	354.7	9.5	37.5
65+ years	23,040	25,473	202,581	8,117,237	13,097,992	12,027,697,308	175.9	352.3	8.8	40.1
<b><i>Levetiracetam</i></b>										
0-2 years	2,715	2,755	14,238	457,920	3,815,239	1,277,590,883	71.2	168.7	5.2	32.2
2-5 years	4,536	4,699	34,497	1,132,564	5,835,484	2,900,048,073	77.7	249.7	7.6	32.8
5-10 years	6,456	6,800	57,750	1,916,718	8,462,858	5,164,218,164	76.3	296.9	8.9	33.2
10-17 years	10,152	10,726	93,417	3,143,650	11,330,782	7,852,554,569	89.6	309.7	9.2	33.7
17-40 years	42,584	46,141	325,625	11,172,164	36,641,274	24,282,235,328	116.2	262.4	7.6	34.3
40-65 years	73,452	79,214	555,823	20,006,178	35,500,567	30,694,671,272	206.9	272.4	7.6	36.0
65+ years	58,246	62,116	447,525	16,715,325	13,092,373	12,014,693,043	444.9	287.0	7.7	37.4

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lorazepam</b>										
0-2 years	846	868	1,400	26,516	3,816,229	1,278,342,966	22.2	31.3	1.7	18.9
2-5 years	1,800	1,931	3,048	53,197	5,837,966	2,902,370,055	30.8	29.6	1.7	17.5
5-10 years	6,023	6,592	10,232	156,407	8,466,728	5,167,819,092	71.1	26.0	1.7	15.3
10-17 years	33,304	36,563	62,157	1,001,267	11,334,688	7,852,766,376	293.8	30.1	1.9	16.1
17-40 years	651,215	772,768	1,728,371	32,994,345	36,597,389	24,110,481,278	1,779.4	50.7	2.7	19.1
40-65 years	1,226,290	1,578,461	4,717,332	105,953,869	35,336,154	30,181,464,410	3,470.4	86.4	3.8	22.5
65+ years	600,251	757,112	2,640,197	71,080,504	13,002,518	11,741,865,780	4,616.4	118.4	4.4	26.9
<b>Mephenytoin</b>										
0-2 years	0	0	0	0	3,816,367	1,278,526,039	0.0	---	---	---
2-5 years	0	0	0	0	5,838,147	2,902,805,479	0.0	---	---	---
5-10 years	0	0	0	0	8,467,104	5,169,219,488	0.0	---	---	---
10-17 years	0	0	0	0	11,336,545	7,860,428,350	0.0	---	---	---
17-40 years	0	0	0	0	36,664,463	24,312,651,783	0.0	---	---	---
40-65 years	1	1	1	30	35,535,570	30,745,011,950	0.0	30.0	1.0	30.0
65+ years	0	0	0	0	13,114,993	12,049,526,825	0.0	---	---	---
<b>Oxcarbazepine</b>										
0-2 years	1,078	1,085	5,116	163,769	3,815,984	1,278,198,761	28.2	151.9	4.7	32.0
2-5 years	2,838	2,911	19,467	621,903	5,836,684	2,901,196,385	48.6	219.1	6.9	31.9
5-10 years	9,279	9,750	76,609	2,427,853	8,462,386	5,162,982,447	109.6	261.7	8.3	31.7
10-17 years	20,584	22,085	160,383	5,130,277	11,326,895	7,845,512,503	181.7	249.2	7.8	32.0
17-40 years	49,499	53,839	288,770	9,308,580	36,643,556	24,281,027,790	135.1	188.1	5.8	32.2
40-65 years	48,465	53,241	317,476	11,101,709	35,511,703	30,707,821,186	136.5	229.1	6.6	35.0
65+ years	13,246	14,608	81,777	3,069,159	13,107,893	12,039,640,304	101.1	231.7	6.2	37.5

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Phenobarbital</i></b>										
0-2 years	1,188	1,195	5,583	172,616	3,815,126	1,277,560,481	31.1	145.3	4.7	30.9
2-5 years	624	647	4,051	137,857	5,837,287	2,901,953,820	10.7	220.9	6.5	34.0
5-10 years	500	545	3,944	139,111	8,466,372	5,168,381,069	5.9	278.2	7.9	35.3
10-17 years	626	696	5,182	178,723	11,335,582	7,859,323,542	5.5	285.5	8.3	34.5
17-40 years	7,010	7,750	29,348	925,385	36,661,015	24,307,227,477	19.1	132.0	4.2	31.5
40-65 years	14,623	16,834	78,654	2,938,758	35,523,072	30,726,231,208	41.2	201.0	5.4	37.4
65+ years	14,501	16,340	57,254	2,279,812	13,108,373	12,038,703,353	110.6	157.2	3.9	39.8
<b><i>Phenytoin, phenytoin sodium</i></b>										
0-2 years	309	314	789	24,465	3,816,287	1,278,445,993	8.1	79.2	2.6	31.0
2-5 years	537	551	2,057	63,507	5,838,050	2,902,603,154	9.2	118.3	3.8	30.9
5-10 years	842	865	3,423	110,231	8,466,859	5,168,771,662	9.9	130.9	4.1	32.2
10-17 years	2,489	2,597	10,964	366,547	11,335,934	7,859,204,864	22.0	147.3	4.4	33.4
17-40 years	23,451	26,350	139,412	4,844,452	36,646,790	24,290,130,726	64.0	206.6	5.9	34.7
40-65 years	50,952	58,128	367,849	14,037,439	35,469,072	30,663,366,992	143.7	275.5	7.2	38.2
65+ years	41,970	46,360	319,052	13,163,603	13,060,245	11,986,676,298	321.4	313.6	7.6	41.3
<b><i>Pregabalin</i></b>										
0-2 years	22	22	112	3,273	3,816,365	1,278,520,487	0.6	148.8	5.1	29.2
2-5 years	86	88	522	16,140	5,838,127	2,902,772,003	1.5	187.7	6.1	30.9
5-10 years	231	237	1,502	48,474	8,467,058	5,169,122,808	2.7	209.8	6.5	32.3
10-17 years	1,861	1,927	7,708	233,971	11,336,293	7,859,851,834	16.4	125.7	4.1	30.4
17-40 years	73,510	78,554	302,126	9,265,234	36,651,672	24,286,314,527	200.6	126.0	4.1	30.7
40-65 years	273,754	299,188	1,396,200	46,458,961	35,470,933	30,612,570,120	771.8	169.7	5.1	33.3
65+ years	137,258	149,727	693,417	23,759,588	13,072,973	11,973,404,786	1,049.9	173.1	5.1	34.3

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Primidone</b>										
0-2 years	8	8	25	721	3,816,364	1,278,523,132	0.2	90.1	3.1	28.8
2-5 years	22	22	164	6,056	5,838,135	2,902,790,226	0.4	275.3	7.5	36.9
5-10 years	65	67	467	16,005	8,467,072	5,169,168,695	0.8	246.2	7.2	34.3
10-17 years	228	240	1,219	39,837	11,336,435	7,860,260,075	2.0	174.7	5.3	32.7
17-40 years	3,195	3,440	16,012	538,053	36,663,120	24,310,706,163	8.7	168.4	5.0	33.6
40-65 years	19,117	21,497	123,575	4,806,089	35,523,933	30,728,180,810	53.8	251.4	6.5	38.9
65+ years	36,474	42,498	265,766	11,611,790	13,094,875	12,015,825,221	278.5	318.4	7.3	43.7
<b>Rufinamide</b>										
0-2 years	50	50	163	4,957	3,816,364	1,278,518,391	1.3	99.1	3.3	30.4
2-5 years	187	191	1,320	41,881	5,838,107	2,902,740,683	3.2	224.0	7.1	31.7
5-10 years	338	350	2,689	85,204	8,467,006	5,169,073,293	4.0	252.1	8.0	31.7
10-17 years	428	437	3,646	117,877	11,336,422	7,860,229,222	3.8	275.4	8.5	32.3
17-40 years	413	427	4,033	134,869	36,664,304	24,312,428,122	1.1	326.6	9.8	33.4
40-65 years	97	101	758	26,038	35,535,529	30,744,964,072	0.3	268.4	7.8	34.4
65+ years	7	7	38	1,372	13,114,991	12,049,524,785	0.1	196.0	5.4	36.1
<b>Tiagabine</b>										
0-2 years	5	5	7	163	3,816,364	1,278,524,974	0.1	32.6	1.4	23.3
2-5 years	17	17	47	1,319	5,838,135	2,902,795,718	0.3	77.6	2.8	28.1
5-10 years	133	137	592	18,488	8,467,056	5,169,154,294	1.6	139.0	4.5	31.2
10-17 years	509	523	2,733	87,553	11,336,382	7,860,112,594	4.5	172.0	5.4	32.0
17-40 years	6,873	7,177	25,952	770,095	36,663,025	24,309,445,075	18.7	112.0	3.8	29.7
40-65 years	12,940	13,722	57,063	1,787,872	35,532,618	30,737,681,766	36.4	138.2	4.4	31.3
65+ years	1,711	1,789	7,448	237,574	13,114,316	12,048,500,781	13.0	138.9	4.4	31.9

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>										
0-2 years	865	886	5,268	163,391	3,815,986	1,278,209,104	22.7	188.9	6.1	31.0
2-5 years	1,243	1,278	7,996	265,940	5,837,321	2,901,977,776	21.3	214.0	6.4	33.3
5-10 years	5,404	5,701	31,955	1,043,407	8,465,214	5,166,466,782	63.8	193.1	5.9	32.7
10-17 years	30,288	32,519	148,467	4,908,957	11,329,846	7,847,295,107	267.3	162.1	4.9	33.1
17-40 years	227,778	252,750	1,160,862	38,970,066	36,599,742	24,200,620,769	622.3	171.1	5.1	33.6
40-65 years	262,785	298,339	1,665,655	60,897,489	35,434,076	30,566,069,183	741.6	231.7	6.3	36.6
65+ years	34,716	38,285	181,365	7,213,221	13,100,550	12,027,727,429	265.0	207.8	5.2	39.8
<b><i>Valproic acid</i></b>										
0-2 years	6	6	7	210	3,816,366	1,278,525,261	0.2	35.0	1.2	30.0
2-5 years	39	40	113	3,958	5,838,146	2,902,797,328	0.7	101.5	2.9	35.0
5-10 years	332	359	1,421	55,581	8,467,067	5,169,116,921	3.9	167.4	4.3	39.1
10-17 years	1,706	1,860	6,438	254,566	11,336,374	7,859,823,552	15.0	149.2	3.8	39.5
17-40 years	11,076	12,507	44,601	1,819,190	36,662,984	24,308,250,660	30.2	164.2	4.0	40.8
40-65 years	15,076	18,709	91,945	4,201,029	35,532,103	30,735,474,907	42.4	278.7	6.1	45.7
65+ years	6,170	7,476	37,009	1,826,603	13,113,200	12,045,440,536	47.1	296.0	6.0	49.4
<b><i>Vigabatrin</i></b>										
0-2 years	132	133	785	23,793	3,816,340	1,278,490,082	3.5	180.3	5.9	30.3
2-5 years	62	62	436	13,658	5,838,092	2,902,772,573	1.1	220.3	7.0	31.3
5-10 years	42	43	438	13,418	8,467,070	5,169,192,159	0.5	319.5	10.4	30.6
10-17 years	37	37	374	11,478	11,336,527	7,860,407,716	0.3	310.2	10.1	30.7
17-40 years	31	31	343	10,274	36,664,450	24,312,635,011	0.1	331.4	11.1	30.0
40-65 years	9	9	74	2,398	35,535,568	30,745,007,708	0.0	266.4	8.2	32.4
65+ years	1	1	1	30	13,114,993	12,049,526,788	0.0	30.0	1.0	30.0

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Zonisamide</b>										
0-2 years	388	391	2,419	74,030	3,816,241	1,278,409,083	10.2	190.8	6.2	30.6
2-5 years	647	669	4,886	155,722	5,837,772	2,902,413,887	11.1	240.7	7.6	31.9
5-10 years	1,248	1,303	11,533	378,729	8,466,350	5,168,233,572	14.7	303.5	9.2	32.8
10-17 years	3,086	3,240	24,778	804,301	11,335,047	7,858,255,798	27.2	260.6	8.0	32.5
17-40 years	19,039	20,374	105,153	3,443,106	36,657,836	24,302,072,975	51.9	180.8	5.5	32.7
40-65 years	25,404	27,422	145,798	4,970,258	35,526,682	30,729,300,403	71.5	195.6	5.7	34.1
65+ years	4,709	5,040	27,869	1,076,363	13,112,810	12,046,187,635	35.9	228.6	5.9	38.6



**Table 3a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>									
Female	130,157	381,914	10,850,208	62,049,909	54,465,384,511	209.8	83.4	2.9	28.4
Male	98,654	224,819	5,689,079	59,118,797	50,463,171,904	166.9	57.7	2.3	25.3
Unknown	163	419	11,270	120,385	144,678,338	135.4	69.1	2.6	26.9
<b>Carbamazepine</b>									
Female	181,928	2,045,856	77,184,899	62,049,909	54,465,384,511	293.2	424.3	11.2	37.7
Male	131,652	1,675,412	62,660,979	59,118,797	50,463,171,904	222.7	476.0	12.7	37.4
Unknown	250	2,741	103,281	120,385	144,678,338	207.7	413.1	11.0	37.7
<b>Clobazam</b>									
Female	330	1,143	36,912	62,049,909	54,465,384,511	0.5	111.9	3.5	32.3
Male	361	1,264	41,434	59,118,797	50,463,171,904	0.6	114.8	3.5	32.8
Unknown	0	0	0	120,385	144,678,338	0.0	---	---	---
<b>Clonazepam</b>									
Female	1,271,059	9,996,389	316,867,025	62,049,909	54,465,384,511	2,048.4	249.3	7.9	31.7
Male	693,149	5,625,906	179,077,769	59,118,797	50,463,171,904	1,172.5	258.4	8.1	31.8
Unknown	1,601	10,279	304,890	120,385	144,678,338	1,329.9	190.4	6.4	29.7
<b>Diazepam</b>									
Female	1,842,969	6,100,748	130,885,760	62,049,909	54,465,384,511	2,970.1	71.0	3.3	21.5
Male	1,062,908	3,839,690	88,078,969	59,118,797	50,463,171,904	1,797.9	82.9	3.6	22.9
Unknown	2,365	6,509	127,532	120,385	144,678,338	1,964.5	53.9	2.8	19.6
<b>Ethosuxamide</b>									
Female	5,091	63,950	2,280,797	62,049,909	54,465,384,511	8.2	448.0	12.6	35.7
Male	3,364	40,582	1,433,008	59,118,797	50,463,171,904	5.7	426.0	12.1	35.3
Unknown	17	286	8,962	120,385	144,678,338	14.1	527.2	16.8	31.3
<b>Ezogabine</b>									
Female	32	94	2,761	62,049,909	54,465,384,511	0.1	86.3	2.9	29.4
Male	26	38	1,296	59,118,797	50,463,171,904	0.0	49.8	1.5	34.1
Unknown	0	0	0	120,385	144,678,338	0.0	---	---	---

**Table 3a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Felbamate</i></b>									
Female	1,621	28,925	1,026,638	62,049,909	54,465,384,511	2.6	633.3	17.8	35.5
Male	1,605	30,629	1,043,396	59,118,797	50,463,171,904	2.7	650.1	19.1	34.1
Unknown	7	78	2,267	120,385	144,678,338	5.8	323.9	11.1	29.1
<b><i>Gabapentin</i></b>									
Female	1,929,856	13,637,681	501,306,752	62,049,909	54,465,384,511	3,110.2	259.8	7.1	36.8
Male	1,158,776	7,591,837	279,194,694	59,118,797	50,463,171,904	1,960.1	240.9	6.6	36.8
Unknown	1,573	8,907	299,468	120,385	144,678,338	1,306.6	190.4	5.7	33.6
<b><i>Lacosamide</i></b>									
Female	8,378	59,874	1,961,597	62,049,909	54,465,384,511	13.5	234.1	7.1	32.8
Male	6,354	47,938	1,565,632	59,118,797	50,463,171,904	10.7	246.4	7.5	32.7
Unknown	15	79	2,619	120,385	144,678,338	12.5	174.6	5.3	33.2
<b><i>Lamotrigine</i></b>									
Female	478,885	5,197,994	184,984,274	62,049,909	54,465,384,511	771.8	386.3	10.9	35.6
Male	246,723	2,797,313	99,449,964	59,118,797	50,463,171,904	417.3	403.1	11.3	35.6
Unknown	822	7,829	265,705	120,385	144,678,338	682.8	323.2	9.5	33.9
<b><i>Levetiracetam</i></b>									
Female	188,960	1,871,843	65,895,041	62,049,909	54,465,384,511	304.5	348.7	9.9	35.2
Male	154,301	1,561,683	55,255,313	59,118,797	50,463,171,904	261.0	358.1	10.1	35.4
Unknown	268	2,597	92,612	120,385	144,678,338	222.6	345.6	9.7	35.7
<b><i>Lorazepam</i></b>									
Female	2,274,304	12,075,102	310,644,413	62,049,909	54,465,384,511	3,665.3	136.6	5.3	25.7
Male	1,109,700	5,450,861	139,525,053	59,118,797	50,463,171,904	1,877.1	125.7	4.9	25.6
Unknown	2,325	9,175	219,136	120,385	144,678,338	1,931.3	94.3	3.9	23.9
<b><i>Mephenytoin</i></b>									
Female	1	1	30	62,049,909	54,465,384,511	0.0	30.0	1.0	30.0
Male	0	0	0	59,118,797	50,463,171,904	0.0	---	---	---
Unknown	0	0	0	120,385	144,678,338	0.0	---	---	---

**Table 3a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Oxcarbazepine</i></b>									
Female	149,708	1,346,396	45,470,734	62,049,909	54,465,384,511	241.3	303.7	9.0	33.8
Male	112,166	1,153,823	38,654,522	59,118,797	50,463,171,904	189.7	344.6	10.3	33.5
Unknown	363	3,345	107,468	120,385	144,678,338	301.5	296.1	9.2	32.1
<b><i>Phenobarbital</i></b>									
Female	42,541	513,528	19,318,147	62,049,909	54,465,384,511	68.6	454.1	12.1	37.6
Male	35,639	422,207	15,590,133	59,118,797	50,463,171,904	60.3	437.4	11.8	36.9
Unknown	54	618	19,375	120,385	144,678,338	44.9	358.8	11.4	31.4
<b><i>Phenytoin, phenytoin sodium</i></b>									
Female	152,605	2,118,709	77,846,051	62,049,909	54,465,384,511	245.9	510.1	13.9	36.7
Male	171,364	2,459,176	92,609,296	59,118,797	50,463,171,904	289.9	540.4	14.4	37.7
Unknown	174	2,387	85,222	120,385	144,678,338	144.5	489.8	13.7	35.7
<b><i>Pregabalin</i></b>									
Female	528,696	3,290,038	109,620,439	62,049,909	54,465,384,511	852.0	207.3	6.2	33.3
Male	270,191	1,596,269	53,736,314	59,118,797	50,463,171,904	457.0	198.9	5.9	33.7
Unknown	336	1,942	67,071	120,385	144,678,338	279.1	199.6	5.8	34.5
<b><i>Primidone</i></b>									
Female	59,696	649,076	25,702,712	62,049,909	54,465,384,511	96.2	430.6	10.9	39.6
Male	48,565	521,701	21,449,117	59,118,797	50,463,171,904	82.1	441.7	10.7	41.1
Unknown	43	326	11,346	120,385	144,678,338	35.7	263.9	7.6	34.8
<b><i>Rufinamide</i></b>									
Female	976	9,018	287,197	62,049,909	54,465,384,511	1.6	294.3	9.2	31.8
Male	1,077	10,075	327,435	59,118,797	50,463,171,904	1.8	304.0	9.4	32.5
Unknown	2	30	898	120,385	144,678,338	1.7	449.0	15.0	29.9
<b><i>Tiagabine</i></b>									
Female	23,877	149,059	4,799,915	62,049,909	54,465,384,511	38.5	201.0	6.2	32.2
Male	14,157	92,298	2,936,662	59,118,797	50,463,171,904	23.9	207.4	6.5	31.8
Unknown	42	224	7,113	120,385	144,678,338	34.9	169.4	5.3	31.8

**Table 3a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>									
Female	751,283	5,947,845	210,520,738	62,049,909	54,465,384,511	1,210.8	280.2	7.9	35.4
Male	179,054	1,258,442	43,940,163	59,118,797	50,463,171,904	302.9	245.4	7.0	34.9
Unknown	1,140	8,617	286,782	120,385	144,678,338	947.0	251.6	7.6	33.3
<b><i>Valproic acid</i></b>									
Female	26,392	167,247	6,917,498	62,049,909	54,465,384,511	42.5	262.1	6.3	41.4
Male	23,953	172,366	6,874,008	59,118,797	50,463,171,904	40.5	287.0	7.2	39.9
Unknown	18	110	4,290	120,385	144,678,338	15.0	238.3	6.1	39.0
<b><i>Vigabatrin</i></b>									
Female	220	2,155	65,946	62,049,909	54,465,384,511	0.4	299.8	9.8	30.6
Male	215	1,881	56,983	59,118,797	50,463,171,904	0.4	265.0	8.7	30.3
Unknown	2	10	290	120,385	144,678,338	1.7	145.0	5.0	29.0
<b><i>Zonisamide</i></b>									
Female	66,079	525,403	17,950,082	62,049,909	54,465,384,511	106.5	271.6	8.0	34.2
Male	27,109	263,028	9,053,134	59,118,797	50,463,171,904	45.9	334.0	9.7	34.4
Unknown	97	736	22,854	120,385	144,678,338	80.6	235.6	7.6	31.1

**Table 3b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>										
Female	101,823	112,885	215,286	5,326,165	51,170,317	43,847,033,816	199.0	52.3	2.1	24.7
Male	80,051	88,330	141,072	3,000,334	48,109,746	40,381,481,515	166.4	37.5	1.8	21.3
Unknown	128	141	243	5,984	109,752	113,760,229	116.6	46.8	1.9	24.6
<b>Carbamazepine</b>										
Female	87,396	101,655	498,284	19,651,609	51,123,959	43,790,418,304	170.9	224.9	5.7	39.4
Male	55,559	64,533	364,030	14,425,178	48,067,949	40,335,697,148	115.6	259.6	6.6	39.6
Unknown	115	126	865	38,293	109,738	113,690,890	104.8	333.0	7.5	44.3
<b>Clobazam</b>										
Female	276	277	948	30,708	51,177,910	43,876,585,907	0.5	111.3	3.4	32.4
Male	296	298	987	33,490	48,113,618	40,401,752,912	0.6	113.1	3.3	33.9
Unknown	0	0	0	0	109,755	113,795,125	0.0	---	---	---
<b>Clonazepam</b>										
Female	779,062	958,099	4,294,410	133,121,429	50,941,208	43,386,848,547	1,529.3	170.9	5.5	31.0
Male	420,988	503,875	2,442,352	76,084,974	47,981,856	40,138,317,577	877.4	180.7	5.8	31.2
Unknown	1,068	1,240	5,426	158,575	109,628	113,274,172	974.2	148.5	5.1	29.2
<b>Diazepam</b>										
Female	1,426,123	1,740,179	3,491,007	62,992,704	51,071,177	43,393,156,195	2,792.4	44.2	2.4	18.0
Male	810,262	953,656	2,075,785	40,248,590	48,042,828	40,126,332,969	1,686.5	49.7	2.6	19.4
Unknown	1,838	2,060	3,941	65,315	109,697	113,268,628	1,675.5	35.5	2.1	16.6
<b>Ethosuxamide</b>										
Female	2,386	2,712	24,681	874,397	51,176,442	43,874,064,475	4.7	366.5	10.3	35.4
Male	1,613	1,793	16,440	574,466	48,112,800	40,400,167,477	3.4	356.1	10.2	34.9
Unknown	11	13	172	5,724	109,755	113,784,355	10.0	520.4	15.6	33.3
<b>Ezogabine</b>										
Female	26	26	76	2,221	51,177,929	43,876,618,915	0.1	85.4	2.9	29.2
Male	22	22	28	1,028	48,113,636	40,401,787,267	0.0	46.7	1.3	36.7
Unknown	0	0	0	0	109,755	113,795,125	0.0	---	---	---

**Table 3b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Felbamate</i></b>										
Female	497	572	6,337	229,267	51,177,167	43,875,629,015	1.0	461.3	12.8	36.2
Male	488	530	6,791	231,209	48,112,883	40,400,807,470	1.0	473.8	13.9	34.0
Unknown	4	4	8	229	109,753	113,792,602	3.6	57.3	2.0	28.6
<b><i>Gabapentin</i></b>										
Female	1,270,317	1,497,643	6,685,601	248,924,638	50,871,010	43,189,647,820	2,497.1	196.0	5.3	37.2
Male	768,617	888,157	3,834,147	142,763,445	47,940,696	40,015,540,195	1,603.3	185.7	5.0	37.2
Unknown	1,102	1,220	4,829	162,456	109,661	113,312,961	1,004.9	147.4	4.4	33.6
<b><i>Lacosamide</i></b>										
Female	6,032	6,211	44,003	1,447,432	51,176,913	43,874,388,798	11.8	240.0	7.3	32.9
Male	4,381	4,507	34,341	1,124,499	48,112,720	40,400,150,946	9.1	256.7	7.8	32.7
Unknown	10	10	45	1,209	109,754	113,791,866	9.1	120.9	4.5	26.9
<b><i>Lamotrigine</i></b>										
Female	248,423	277,404	2,204,829	79,028,202	51,052,984	43,677,036,668	486.6	318.1	8.9	35.8
Male	124,851	137,048	1,166,130	41,742,095	48,045,866	40,297,356,879	259.9	334.3	9.3	35.8
Unknown	470	513	4,079	134,585	109,685	113,476,320	428.5	286.4	8.7	33.0
<b><i>Levetiracetam</i></b>										
Female	109,082	117,986	890,188	31,646,276	51,135,017	43,803,974,432	213.3	290.1	8.2	35.6
Male	87,556	94,300	740,144	26,532,256	48,076,770	40,342,325,630	182.1	303.0	8.5	35.8
Unknown	154	165	1,326	47,482	109,735	113,696,589	140.3	308.3	8.6	35.8
<b><i>Lorazepam</i></b>										
Female	1,663,988	2,148,463	6,346,329	147,144,198	50,944,901	43,126,325,586	3,266.3	88.4	3.8	23.2
Male	821,916	1,003,835	2,964,681	68,428,669	48,010,166	40,069,620,344	1,712.0	83.3	3.6	23.1
Unknown	1,713	1,997	5,530	124,253	109,656	113,182,416	1,562.2	72.5	3.2	22.5
<b><i>Mephenytoin</i></b>										
Female	1	1	1	30	51,177,931	43,876,620,534	0.0	30.0	1.0	30.0
Male	0	0	0	0	48,113,639	40,401,788,014	0.0	---	---	---
Unknown	0	0	0	0	109,755	113,795,125	0.0	---	---	---

**Table 3b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Oxcarbazepine</i></b>										
Female	84,016	92,589	560,532	18,888,364	51,148,597	43,820,191,311	164.3	224.8	6.7	33.7
Male	59,086	64,728	475,156	15,815,445	48,088,543	40,356,524,901	122.9	267.7	8.0	33.3
Unknown	192	202	1,322	42,437	109,733	113,667,565	175.0	221.0	6.9	32.1
<b><i>Phenobarbital</i></b>										
Female	21,162	24,192	106,089	3,942,261	51,165,623	43,855,174,001	41.4	186.3	5.0	37.2
Male	17,604	19,784	89,727	3,283,596	48,103,679	40,384,431,923	36.6	186.5	5.1	36.6
Unknown	30	31	336	9,608	109,752	113,772,658	27.3	320.3	11.2	28.6
<b><i>Phenytoin, phenytoin sodium</i></b>										
Female	58,561	65,935	419,606	15,947,987	51,119,604	43,798,881,959	114.6	272.3	7.2	38.0
Male	61,136	69,143	449,718	17,754,172	48,043,476	40,310,639,691	127.3	290.4	7.4	39.5
Unknown	84	87	744	26,408	109,729	113,708,587	76.6	314.4	8.9	35.5
<b><i>Pregabalin</i></b>										
Female	319,772	350,608	1,651,035	54,749,381	51,105,084	43,718,514,132	625.7	171.2	5.2	33.2
Male	164,871	178,861	798,093	26,708,521	48,078,272	40,324,386,510	342.9	162.0	4.8	33.5
Unknown	251	274	1,311	46,249	109,739	113,688,371	228.7	184.3	5.2	35.3
<b><i>Primidone</i></b>										
Female	32,088	36,719	224,046	9,187,551	51,160,833	43,847,924,308	62.7	286.3	7.0	41.0
Male	26,732	31,025	191,420	8,203,968	48,100,038	40,377,783,268	55.6	306.9	7.2	42.9
Unknown	27	28	129	4,501	109,753	113,780,505	24.6	166.7	4.8	34.9
<b><i>Rufinamide</i></b>										
Female	701	721	6,532	210,749	51,177,798	43,876,294,323	1.4	300.6	9.3	32.3
Male	811	840	7,785	254,604	48,113,501	40,401,423,900	1.7	313.9	9.6	32.7
Unknown	2	2	30	898	109,755	113,794,104	1.8	449.0	15.0	29.9
<b><i>Tiagabine</i></b>										
Female	14,026	14,844	60,370	1,878,290	51,175,152	43,869,123,505	27.4	133.9	4.3	31.1
Male	8,080	8,507	35,410	1,086,804	48,111,822	40,397,341,938	16.8	134.5	4.4	30.7
Unknown	19	19	67	1,964	109,755	113,783,335	17.3	103.4	3.5	29.3

**Table 3b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>										
Female	445,771	507,289	2,738,747	97,321,073	51,041,276	43,605,010,775	873.4	218.3	6.1	35.5
Male	111,215	121,652	585,883	20,555,109	48,086,426	40,343,974,460	231.3	184.8	5.3	35.1
Unknown	732	817	4,652	156,170	109,686	113,401,322	667.4	213.3	6.4	33.6
<b><i>Valproic acid</i></b>										
Female	18,412	22,105	96,131	4,388,921	51,175,222	43,866,989,144	36.0	238.4	5.2	45.7
Male	15,591	18,842	91,436	4,061,389	48,110,420	40,392,684,201	32.4	260.5	5.9	44.4
Unknown	10	10	67	2,820	109,754	113,789,281	9.1	282.0	6.7	42.1
<b><i>Vigabatrin</i></b>										
Female	153	156	1,541	47,154	51,177,894	43,876,546,486	0.3	308.2	10.1	30.6
Male	154	158	1,412	42,925	48,113,604	40,401,722,807	0.3	278.7	9.2	30.4
Unknown	2	2	10	290	109,755	113,794,564	1.8	145.0	5.0	29.0
<b><i>Zonisamide</i></b>										
Female	39,190	42,396	236,921	7,981,169	51,166,586	43,853,767,391	76.6	203.7	6.0	33.7
Male	14,939	15,975	107,266	3,658,799	48,107,775	40,391,366,591	31.1	244.9	7.2	34.1
Unknown	58	68	277	8,718	109,750	113,763,262	52.8	150.3	4.8	31.5



Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>									
2004	15,890	35,585	965,186	23,852,540	7,080,534,600	66.6	60.7	2.2	27.1
2005	16,962	35,776	952,941	24,633,820	7,256,197,886	68.9	56.2	2.1	26.6
2006	19,888	39,076	1,049,334	26,418,643	7,874,284,484	75.3	52.8	2.0	26.9
2007	29,707	62,497	1,681,206	33,458,945	9,332,406,812	88.8	56.6	2.1	26.9
2008	47,591	105,324	2,811,911	60,531,945	17,574,413,035	78.6	59.1	2.2	26.7
2009	44,759	96,000	2,601,820	56,699,065	16,989,471,078	78.9	58.1	2.1	27.1
2010	45,000	95,291	2,605,750	55,259,872	16,430,588,163	81.4	57.9	2.1	27.3
2011	43,207	90,380	2,532,205	54,197,789	16,009,092,991	79.7	58.6	2.1	28.0
2012	25,199	47,223	1,350,204	34,157,358	6,526,245,704	73.8	53.6	1.9	28.6
<b>Carbamazepine</b>									
2004	52,883	324,857	11,904,528	23,852,540	7,080,534,600	221.7	225.1	6.1	36.6
2005	51,677	302,870	11,257,288	24,633,820	7,256,197,886	209.8	217.8	5.9	37.2
2006	50,242	280,687	10,967,863	26,418,643	7,874,284,484	190.2	218.3	5.6	39.1
2007	81,031	440,026	15,999,114	33,458,945	9,332,406,812	242.2	197.4	5.4	36.4
2008	108,194	672,778	24,073,319	60,531,945	17,574,413,035	178.7	222.5	6.2	35.8
2009	92,954	529,850	19,895,000	56,699,065	16,989,471,078	163.9	214.0	5.7	37.5
2010	89,818	491,758	18,866,518	55,259,872	16,430,588,163	162.5	210.1	5.5	38.4
2011	86,553	456,222	17,925,419	54,197,789	16,009,092,991	159.7	207.1	5.3	39.3
2012	58,693	224,961	9,060,110	34,157,358	6,526,245,704	171.8	154.4	3.8	40.3
<b>Clobazam</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	0	0	0	24,633,820	7,256,197,886	0.0	---	---	---
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	0	0	0	56,699,065	16,989,471,078	0.0	---	---	---
2010	0	0	0	55,259,872	16,430,588,163	0.0	---	---	---
2011	8	8	240	54,197,789	16,009,092,991	0.0	30.0	1.0	30.0
2012	688	2,399	78,106	34,157,358	6,526,245,704	2.0	113.5	3.5	32.6

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Clonazepam</b>									
2004	216,286	1,064,047	32,486,032	23,852,540	7,080,534,600	906.8	150.2	4.9	30.5
2005	230,700	1,090,740	33,626,375	24,633,820	7,256,197,886	936.5	145.8	4.7	30.8
2006	225,054	942,697	30,197,823	26,418,643	7,874,284,484	851.9	134.2	4.2	32.0
2007	323,654	1,323,745	42,076,792	33,458,945	9,332,406,812	967.3	130.0	4.1	31.8
2008	585,827	2,583,865	80,954,756	60,531,945	17,574,413,035	967.8	138.2	4.4	31.3
2009	601,408	2,638,788	83,298,124	56,699,065	16,989,471,078	1,060.7	138.5	4.4	31.6
2010	588,800	2,599,630	82,996,555	55,259,872	16,430,588,163	1,065.5	141.0	4.4	31.9
2011	557,944	2,306,724	74,831,228	54,197,789	16,009,092,991	1,029.5	134.1	4.1	32.4
2012	337,924	1,082,338	35,781,999	34,157,358	6,526,245,704	989.3	105.9	3.2	33.1
<b>Diazepam</b>									
2004	299,192	905,119	20,921,142	23,852,540	7,080,534,600	1,254.3	69.9	3.0	23.1
2005	310,102	874,571	19,901,192	24,633,820	7,256,197,886	1,258.8	64.2	2.8	22.8
2006	302,394	697,265	14,995,757	26,418,643	7,874,284,484	1,144.6	49.6	2.3	21.5
2007	400,330	942,875	21,049,598	33,458,945	9,332,406,812	1,196.5	52.6	2.4	22.3
2008	682,968	1,636,853	35,445,064	60,531,945	17,574,413,035	1,128.3	51.9	2.4	21.7
2009	663,598	1,577,398	34,180,213	56,699,065	16,989,471,078	1,170.4	51.5	2.4	21.7
2010	628,700	1,486,734	32,307,037	55,259,872	16,430,588,163	1,137.7	51.4	2.4	21.7
2011	558,171	1,255,541	27,628,428	54,197,789	16,009,092,991	1,029.9	49.5	2.2	22.0
2012	290,035	570,591	12,663,830	34,157,358	6,526,245,704	849.1	43.7	2.0	22.2
<b>Ethosuxamide</b>									
2004	1,192	6,991	252,959	23,852,540	7,080,534,600	5.0	212.2	5.9	36.2
2005	1,208	6,960	251,981	24,633,820	7,256,197,886	4.9	208.6	5.8	36.2
2006	1,211	6,759	250,304	26,418,643	7,874,284,484	4.6	206.7	5.6	37.0
2007	1,517	8,419	301,885	33,458,945	9,332,406,812	4.5	199.0	5.5	35.9
2008	2,695	16,409	567,876	60,531,945	17,574,413,035	4.5	210.7	6.1	34.6
2009	2,859	17,190	599,955	56,699,065	16,989,471,078	5.0	209.8	6.0	34.9
2010	2,992	17,943	634,540	55,259,872	16,430,588,163	5.4	212.1	6.0	35.4
2011	2,962	16,772	595,215	54,197,789	16,009,092,991	5.5	201.0	5.7	35.5
2012	1,814	7,375	268,052	34,157,358	6,526,245,704	5.3	147.8	4.1	36.3

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Ezogabine</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	0	0	0	24,633,820	7,256,197,886	0.0	---	---	---
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	0	0	0	56,699,065	16,989,471,078	0.0	---	---	---
2010	0	0	0	55,259,872	16,430,588,163	0.0	---	---	---
2011	0	0	0	54,197,789	16,009,092,991	0.0	---	---	---
2012	58	132	4,057	34,157,358	6,526,245,704	0.2	69.9	2.3	30.7
<b>Felbamate</b>									
2004	509	4,135	141,606	23,852,540	7,080,534,600	2.1	278.2	8.1	34.2
2005	540	4,161	142,998	24,633,820	7,256,197,886	2.2	264.8	7.7	34.4
2006	552	4,175	147,768	26,418,643	7,874,284,484	2.1	267.7	7.6	35.4
2007	871	6,194	210,704	33,458,945	9,332,406,812	2.6	241.9	7.1	34.0
2008	1,354	10,831	366,540	60,531,945	17,574,413,035	2.2	270.7	8.0	33.8
2009	1,217	9,135	320,384	56,699,065	16,989,471,078	2.1	263.3	7.5	35.1
2010	1,211	8,752	310,717	55,259,872	16,430,588,163	2.2	256.6	7.2	35.5
2011	1,199	8,355	294,713	54,197,789	16,009,092,991	2.2	245.8	7.0	35.3
2012	815	3,894	136,871	34,157,358	6,526,245,704	2.4	167.9	4.8	35.1
<b>Gabapentin</b>									
2004	241,691	1,119,364	37,600,410	23,852,540	7,080,534,600	1,013.3	155.6	4.6	33.6
2005	244,263	1,064,868	36,707,337	24,633,820	7,256,197,886	991.6	150.3	4.4	34.5
2006	251,538	985,931	36,991,424	26,418,643	7,874,284,484	952.1	147.1	3.9	37.5
2007	501,829	1,937,383	68,251,721	33,458,945	9,332,406,812	1,499.8	136.0	3.9	35.2
2008	783,439	3,386,411	118,459,752	60,531,945	17,574,413,035	1,294.3	151.2	4.3	35.0
2009	810,267	3,311,617	119,906,340	56,699,065	16,989,471,078	1,429.1	148.0	4.1	36.2
2010	883,430	3,582,141	133,186,666	55,259,872	16,430,588,163	1,598.7	150.8	4.1	37.2
2011	951,689	3,761,325	145,658,745	54,197,789	16,009,092,991	1,756.0	153.1	4.0	38.7
2012	682,735	2,089,385	84,038,519	34,157,358	6,526,245,704	1,998.8	123.1	3.1	40.2

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lacosamide</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	0	0	0	24,633,820	7,256,197,886	0.0	---	---	---
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	2,373	7,324	226,679	56,699,065	16,989,471,078	4.2	95.5	3.1	31.0
2010	6,028	29,407	961,523	55,259,872	16,430,588,163	10.9	159.5	4.9	32.7
2011	8,165	44,640	1,457,664	54,197,789	16,009,092,991	15.1	178.5	5.5	32.7
2012	5,912	26,520	883,982	34,157,358	6,526,245,704	17.3	149.5	4.5	33.3
<b>Lamotrigine</b>									
2004	47,140	261,311	8,909,176	23,852,540	7,080,534,600	197.6	189.0	5.5	34.1
2005	62,565	341,976	11,790,865	24,633,820	7,256,197,886	254.0	188.5	5.5	34.5
2006	79,032	424,725	15,313,238	26,418,643	7,874,284,484	299.2	193.8	5.4	36.1
2007	130,388	697,069	24,275,591	33,458,945	9,332,406,812	389.7	186.2	5.3	34.8
2008	243,832	1,447,753	49,772,900	60,531,945	17,574,413,035	402.8	204.1	5.9	34.4
2009	243,150	1,428,806	50,327,841	56,699,065	16,989,471,078	428.8	207.0	5.9	35.2
2010	246,051	1,428,747	51,270,031	55,259,872	16,430,588,163	445.3	208.4	5.8	35.9
2011	243,747	1,334,273	48,873,316	54,197,789	16,009,092,991	449.7	200.5	5.5	36.6
2012	155,576	638,476	24,166,985	34,157,358	6,526,245,704	455.5	155.3	4.1	37.9
<b>Levetiracetam</b>									
2004	19,423	105,922	3,509,497	23,852,540	7,080,534,600	81.4	180.7	5.5	33.1
2005	22,529	123,649	4,183,023	24,633,820	7,256,197,886	91.5	185.7	5.5	33.8
2006	26,673	143,274	5,075,464	26,418,643	7,874,284,484	101.0	190.3	5.4	35.4
2007	54,962	286,683	9,677,187	33,458,945	9,332,406,812	164.3	176.1	5.2	33.8
2008	94,391	556,577	18,771,712	60,531,945	17,574,413,035	155.9	198.9	5.9	33.7
2009	100,736	574,549	20,031,100	56,699,065	16,989,471,078	177.7	198.8	5.7	34.9
2010	113,542	629,192	22,452,095	55,259,872	16,430,588,163	205.5	197.7	5.5	35.7
2011	124,593	664,570	24,339,150	54,197,789	16,009,092,991	229.9	195.3	5.3	36.6
2012	88,640	351,707	13,203,738	34,157,358	6,526,245,704	259.5	149.0	4.0	37.5

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lorazepam</b>									
2004	367,185	1,320,905	32,758,944	23,852,540	7,080,534,600	1,539.4	89.2	3.6	24.8
2005	387,785	1,334,765	32,802,871	24,633,820	7,256,197,886	1,574.2	84.6	3.4	24.6
2006	374,367	1,105,952	27,374,212	26,418,643	7,874,284,484	1,417.1	73.1	3.0	24.8
2007	537,204	1,631,239	41,421,342	33,458,945	9,332,406,812	1,605.6	77.1	3.0	25.4
2008	882,782	2,865,765	72,959,942	60,531,945	17,574,413,035	1,458.4	82.6	3.2	25.5
2009	889,842	2,870,587	73,574,738	56,699,065	16,989,471,078	1,569.4	82.7	3.2	25.6
2010	873,499	2,812,530	73,086,075	55,259,872	16,430,588,163	1,580.7	83.7	3.2	26.0
2011	804,732	2,448,929	65,402,503	54,197,789	16,009,092,991	1,484.8	81.3	3.0	26.7
2012	457,895	1,144,466	31,007,975	34,157,358	6,526,245,704	1,340.5	67.7	2.5	27.1
<b>Mephenytoin</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	1	1	30	24,633,820	7,256,197,886	0.0	30.0	1.0	30.0
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	0	0	0	56,699,065	16,989,471,078	0.0	---	---	---
2010	0	0	0	55,259,872	16,430,588,163	0.0	---	---	---
2011	0	0	0	54,197,789	16,009,092,991	0.0	---	---	---
2012	0	0	0	34,157,358	6,526,245,704	0.0	---	---	---
<b>Oxcarbazepine</b>									
2004	40,221	208,429	6,374,474	23,852,540	7,080,534,600	168.6	158.5	5.2	30.6
2005	39,513	202,926	6,435,211	24,633,820	7,256,197,886	160.4	162.9	5.1	31.7
2006	34,352	175,680	5,912,946	26,418,643	7,874,284,484	130.0	172.1	5.1	33.7
2007	47,807	249,889	8,228,701	33,458,945	9,332,406,812	142.9	172.1	5.2	32.9
2008	75,828	440,494	14,593,534	60,531,945	17,574,413,035	125.3	192.5	5.8	33.1
2009	69,225	380,254	12,955,996	56,699,065	16,989,471,078	122.1	187.2	5.5	34.1
2010	68,127	362,127	12,553,688	55,259,872	16,430,588,163	123.3	184.3	5.3	34.7
2011	65,496	333,696	11,720,225	54,197,789	16,009,092,991	120.8	178.9	5.1	35.1
2012	38,658	150,069	5,457,949	34,157,358	6,526,245,704	113.2	141.2	3.9	36.4

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Phenobarbital</i></b>									
2004	17,733	120,965	4,119,786	23,852,540	7,080,534,600	74.3	232.3	6.8	34.1
2005	16,981	110,716	3,797,727	24,633,820	7,256,197,886	68.9	223.6	6.5	34.3
2006	14,354	76,058	2,942,990	26,418,643	7,874,284,484	54.3	205.0	5.3	38.7
2007	19,155	97,343	3,683,608	33,458,945	9,332,406,812	57.2	192.3	5.1	37.8
2008	25,469	149,650	5,483,373	60,531,945	17,574,413,035	42.1	215.3	5.9	36.6
2009	23,575	132,712	5,009,684	56,699,065	16,989,471,078	41.6	212.5	5.6	37.7
2010	20,618	114,997	4,433,529	55,259,872	16,430,588,163	37.3	215.0	5.6	38.6
2011	18,572	93,190	3,729,153	54,197,789	16,009,092,991	34.3	200.8	5.0	40.0
2012	11,507	40,722	1,727,805	34,157,358	6,526,245,704	33.7	150.2	3.5	42.4
<b><i>Phenytoin, phenytoin sodium</i></b>									
2004	62,506	429,127	15,374,921	23,852,540	7,080,534,600	262.1	246.0	6.9	35.8
2005	59,707	390,738	14,182,747	24,633,820	7,256,197,886	242.4	237.5	6.5	36.3
2006	55,256	333,403	13,077,429	26,418,643	7,874,284,484	209.2	236.7	6.0	39.2
2007	102,176	597,313	21,295,612	33,458,945	9,332,406,812	305.4	208.4	5.8	35.7
2008	123,161	872,372	30,810,398	60,531,945	17,574,413,035	203.5	250.2	7.1	35.3
2009	96,775	632,714	23,774,197	56,699,065	16,989,471,078	170.7	245.7	6.5	37.6
2010	90,195	562,531	21,685,780	55,259,872	16,430,588,163	163.2	240.4	6.2	38.6
2011	85,350	512,435	20,240,454	54,197,789	16,009,092,991	157.5	237.1	6.0	39.5
2012	58,917	249,639	10,099,031	34,157,358	6,526,245,704	172.5	171.4	4.2	40.5
<b><i>Pregabalin</i></b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	9,644	15,513	440,057	24,633,820	7,256,197,886	39.1	45.6	1.6	28.4
2006	53,521	165,546	5,166,714	26,418,643	7,874,284,484	202.6	96.5	3.1	31.2
2007	170,580	563,800	17,515,621	33,458,945	9,332,406,812	509.8	102.7	3.3	31.1
2008	321,350	1,282,617	41,221,799	60,531,945	17,574,413,035	530.9	128.3	4.0	32.1
2009	218,268	946,718	31,761,864	56,699,065	16,989,471,078	385.0	145.5	4.3	33.5
2010	190,921	818,614	28,271,083	55,259,872	16,430,588,163	345.5	148.1	4.3	34.5
2011	174,347	721,647	25,716,351	54,197,789	16,009,092,991	321.7	147.5	4.1	35.6
2012	112,691	373,794	13,330,335	34,157,358	6,526,245,704	329.9	118.3	3.3	35.7

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Primidone</b>									
2004	11,351	65,559	2,485,824	23,852,540	7,080,534,600	47.6	219.0	5.8	37.9
2005	11,475	63,714	2,455,453	24,633,820	7,256,197,886	46.6	214.0	5.6	38.5
2006	11,843	59,465	2,505,527	26,418,643	7,874,284,484	44.8	211.6	5.0	42.1
2007	27,128	129,091	4,869,279	33,458,945	9,332,406,812	81.1	179.5	4.8	37.7
2008	37,348	214,524	8,034,584	60,531,945	17,574,413,035	61.7	215.1	5.7	37.5
2009	33,722	182,609	7,247,209	56,699,065	16,989,471,078	59.5	214.9	5.4	39.7
2010	34,419	180,578	7,423,946	55,259,872	16,430,588,163	62.3	215.7	5.2	41.1
2011	36,318	178,528	7,779,826	54,197,789	16,009,092,991	67.0	214.2	4.9	43.6
2012	27,848	97,035	4,361,527	34,157,358	6,526,245,704	81.5	156.6	3.5	44.9
<b>Rufinamide</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	0	0	0	24,633,820	7,256,197,886	0.0	---	---	---
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	840	3,735	116,870	56,699,065	16,989,471,078	1.5	139.1	4.4	31.3
2010	991	6,283	200,367	55,259,872	16,430,588,163	1.8	202.2	6.3	31.9
2011	1,024	6,492	209,609	54,197,789	16,009,092,991	1.9	204.7	6.3	32.3
2012	553	2,613	88,684	34,157,358	6,526,245,704	1.6	160.4	4.7	33.9
<b>Tiagabine</b>									
2004	19,591	71,888	2,140,004	23,852,540	7,080,534,600	82.1	109.2	3.7	29.8
2005	12,157	49,626	1,525,552	24,633,820	7,256,197,886	49.4	125.5	4.1	30.7
2006	4,492	19,329	648,582	26,418,643	7,874,284,484	17.0	144.4	4.3	33.6
2007	4,933	23,115	752,661	33,458,945	9,332,406,812	14.7	152.6	4.7	32.6
2008	5,779	30,346	1,006,963	60,531,945	17,574,413,035	9.5	174.2	5.3	33.2
2009	3,688	18,673	651,806	56,699,065	16,989,471,078	6.5	176.7	5.1	34.9
2010	2,763	14,000	494,548	55,259,872	16,430,588,163	5.0	179.0	5.1	35.3
2011	2,006	10,414	373,736	54,197,789	16,009,092,991	3.7	186.3	5.2	35.9
2012	1,075	4,190	149,838	34,157,358	6,526,245,704	3.1	139.4	3.9	35.8

**Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>									
2004	86,581	403,068	13,227,940	23,852,540	7,080,534,600	363.0	152.8	4.7	32.8
2005	96,000	429,640	14,255,819	24,633,820	7,256,197,886	389.7	148.5	4.5	33.2
2006	100,698	445,291	15,798,389	26,418,643	7,874,284,484	381.2	156.9	4.4	35.5
2007	146,461	652,047	22,627,927	33,458,945	9,332,406,812	437.7	154.5	4.5	34.7
2008	264,379	1,243,406	42,951,885	60,531,945	17,574,413,035	436.8	162.5	4.7	34.5
2009	261,939	1,202,301	42,365,970	56,699,065	16,989,471,078	462.0	161.7	4.6	35.2
2010	267,171	1,221,055	43,734,282	55,259,872	16,430,588,163	483.5	163.7	4.6	35.8
2011	256,062	1,100,880	40,266,231	54,197,789	16,009,092,991	472.5	157.3	4.3	36.6
2012	155,807	517,216	19,519,240	34,157,358	6,526,245,704	456.1	125.3	3.3	37.7
<b><i>Valproic acid</i></b>									
2004	3,610	13,706	562,553	23,852,540	7,080,534,600	15.1	155.8	3.8	41.0
2005	8,984	23,236	1,035,745	24,633,820	7,256,197,886	36.5	115.3	2.6	44.6
2006	7,674	25,570	983,491	26,418,643	7,874,284,484	29.0	128.2	3.3	38.5
2007	11,856	43,098	1,573,022	33,458,945	9,332,406,812	35.4	132.7	3.6	36.5
2008	15,526	66,325	2,558,310	60,531,945	17,574,413,035	25.6	164.8	4.3	38.6
2009	13,285	55,306	2,253,912	56,699,065	16,989,471,078	23.4	169.7	4.2	40.8
2010	11,634	49,542	2,082,574	55,259,872	16,430,588,163	21.1	179.0	4.3	42.0
2011	10,191	42,785	1,846,944	54,197,789	16,009,092,991	18.8	181.2	4.2	43.2
2012	6,370	20,155	899,245	34,157,358	6,526,245,704	18.6	141.2	3.2	44.6
<b><i>Vigabatrin</i></b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	0	0	0	24,633,820	7,256,197,886	0.0	---	---	---
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	65	119	3,590	56,699,065	16,989,471,078	0.1	55.2	1.8	30.2
2010	235	1,384	43,206	55,259,872	16,430,588,163	0.4	183.9	5.9	31.2
2011	274	1,792	53,905	54,197,789	16,009,092,991	0.5	196.7	6.5	30.1
2012	146	751	22,518	34,157,358	6,526,245,704	0.4	154.2	5.1	30.0



Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Zonisamide</b>									
2004	12,819	56,696	1,783,243	23,852,540	7,080,534,600	53.7	139.1	4.4	31.5
2005	12,255	58,004	1,857,028	24,633,820	7,256,197,886	49.7	151.5	4.7	32.0
2006	9,996	50,123	1,681,899	26,418,643	7,874,284,484	37.8	168.3	5.0	33.6
2007	15,104	74,863	2,499,625	33,458,945	9,332,406,812	45.1	165.5	5.0	33.4
2008	25,987	138,582	4,672,498	60,531,945	17,574,413,035	42.9	179.8	5.3	33.7
2009	24,530	125,886	4,334,792	56,699,065	16,989,471,078	43.3	176.7	5.1	34.4
2010	23,558	120,459	4,224,889	55,259,872	16,430,588,163	42.6	179.3	5.1	35.1
2011	22,712	112,717	4,040,191	54,197,789	16,009,092,991	41.9	177.9	5.0	35.8
2012	13,606	51,837	1,931,905	34,157,358	6,526,245,704	39.8	142.0	3.8	37.3

Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>										
2004	8,954	9,006	12,477	245,783	19,647,025	4,364,700,985	45.6	27.4	1.4	19.7
2005	12,977	13,106	17,991	336,329	21,615,358	6,235,974,751	60.0	25.9	1.4	18.7
2006	14,852	14,970	20,282	393,780	23,279,950	6,544,254,167	63.8	26.5	1.4	19.4
2007	17,428	17,550	23,419	459,190	29,421,177	7,151,923,427	59.2	26.3	1.3	19.6
2008	29,506	29,698	41,167	779,650	50,827,933	11,929,980,125	58.1	26.4	1.4	18.9
2009	34,048	34,349	48,589	956,285	50,751,330	14,709,191,359	67.1	28.1	1.4	19.7
2010	33,908	34,244	48,434	961,335	48,733,745	14,175,441,903	69.6	28.4	1.4	19.8
2011	31,293	31,564	44,046	882,766	47,989,422	13,781,409,033	65.2	28.2	1.4	20.0
2012	16,853	16,869	22,019	433,255	29,080,471	5,449,399,810	58.0	25.7	1.3	19.7
<b>Carbamazepine</b>										
2004	12,009	12,208	31,027	1,205,619	19,617,360	4,355,954,371	61.2	100.4	2.6	38.9
2005	14,390	14,678	36,710	1,387,142	21,585,754	6,225,757,023	66.7	96.4	2.6	37.8
2006	13,717	13,984	35,712	1,384,209	23,251,821	6,535,404,400	59.0	100.9	2.6	38.8
2007	14,661	14,945	36,397	1,420,262	29,371,700	7,142,569,083	49.9	96.9	2.5	39.0
2008	25,052	25,466	61,658	2,205,411	50,765,854	11,912,991,374	49.3	88.0	2.5	35.8
2009	26,185	26,679	66,674	2,417,855	50,700,501	14,693,435,172	51.6	92.3	2.5	36.3
2010	24,755	25,202	63,234	2,358,109	48,687,941	14,161,765,840	50.8	95.3	2.6	37.3
2011	21,919	22,273	53,369	2,042,797	47,943,714	13,768,410,325	45.7	93.2	2.4	38.3
2012	10,854	10,879	21,241	821,481	29,044,852	5,443,518,754	37.4	75.7	2.0	38.7
<b>Clobazam</b>										
2004	0	0	0	0	19,649,857	4,366,981,987	0.0	---	---	---
2005	0	0	0	0	21,618,167	6,239,234,307	0.0	---	---	---
2006	0	0	0	0	23,283,011	6,547,744,271	0.0	---	---	---
2007	0	0	0	0	29,430,864	7,156,154,266	0.0	---	---	---
2008	0	0	0	0	50,837,296	11,937,666,661	0.0	---	---	---
2009	0	0	0	0	50,758,836	14,717,713,662	0.0	---	---	---
2010	0	0	0	0	48,741,181	14,183,830,622	0.0	---	---	---
2011	7	7	7	210	47,996,923	13,789,654,345	0.0	30.0	1.0	30.0
2012	565	568	1,904	63,052	29,087,309	5,453,153,823	1.9	111.6	3.4	33.1

**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Clonazepam</i></b>										
2004	71,890	72,840	186,744	5,264,507	19,550,420	4,329,680,329	367.7	73.2	2.6	28.2
2005	98,760	100,651	255,066	7,273,274	21,511,838	6,186,504,976	459.1	73.6	2.6	28.5
2006	97,509	99,592	231,424	6,736,141	23,184,191	6,498,354,556	420.6	69.1	2.4	29.1
2007	121,991	124,751	318,172	9,370,114	29,266,967	7,098,539,268	416.8	76.8	2.6	29.4
2008	208,392	211,826	484,463	14,030,990	50,557,849	11,831,636,870	412.2	67.3	2.3	29.0
2009	261,469	267,171	648,520	18,799,114	50,486,896	14,582,223,586	517.9	71.9	2.5	29.0
2010	251,251	256,846	627,902	18,408,646	48,470,439	14,052,061,458	518.4	73.3	2.5	29.3
2011	218,481	222,818	515,765	15,256,123	47,730,991	13,661,753,100	457.7	69.8	2.4	29.6
2012	106,278	106,719	202,676	6,000,995	28,885,878	5,397,686,153	367.9	56.5	1.9	29.6
<b><i>Diazepam</i></b>										
2004	146,969	148,992	240,630	3,988,274	19,570,741	4,320,175,101	751.0	27.1	1.6	16.6
2005	206,701	211,177	324,695	4,944,953	21,541,317	6,175,217,263	959.6	23.9	1.6	15.2
2006	207,750	212,026	307,904	4,479,053	23,220,119	6,489,075,254	894.7	21.6	1.5	14.5
2007	242,689	248,097	386,532	6,290,804	29,310,847	7,090,084,344	828.0	25.9	1.6	16.3
2008	387,007	393,258	577,361	8,707,851	50,676,969	11,827,275,182	763.7	22.5	1.5	15.1
2009	464,405	473,298	699,028	10,165,665	50,620,185	14,586,921,759	917.4	21.9	1.5	14.5
2010	441,930	450,358	666,285	9,649,794	48,609,998	14,061,738,996	909.1	21.8	1.5	14.5
2011	377,394	383,258	549,141	7,842,501	47,876,194	13,676,485,885	788.3	20.8	1.5	14.3
2012	174,963	175,431	230,278	3,097,892	28,989,871	5,405,784,008	603.5	17.7	1.3	13.5
<b><i>Ethosuxamide</i></b>										
2004	251	254	824	30,059	19,649,131	4,366,754,604	1.3	119.8	3.3	36.5
2005	315	318	1,182	43,516	21,617,439	6,238,926,409	1.5	138.1	3.8	36.8
2006	299	306	1,046	38,518	23,282,253	6,547,442,871	1.3	128.8	3.5	36.8
2007	362	367	1,259	44,128	29,429,900	7,155,826,508	1.2	121.9	3.5	35.1
2008	587	594	2,182	73,159	50,835,570	11,937,124,376	1.2	124.6	3.7	33.5
2009	778	786	3,140	106,199	50,757,090	14,717,008,546	1.5	136.5	4.0	33.8
2010	842	854	3,383	116,779	48,739,390	14,183,097,398	1.7	138.7	4.0	34.5
2011	702	705	2,748	93,173	47,995,073	13,788,907,710	1.5	132.7	3.9	33.9
2012	334	334	920	33,000	29,086,081	5,452,927,885	1.1	98.8	2.8	35.9

Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Ezogabine</b>										
2004	0	0	0	0	19,649,857	4,366,981,987	0.0	---	---	---
2005	0	0	0	0	21,618,167	6,239,234,307	0.0	---	---	---
2006	0	0	0	0	23,283,011	6,547,744,271	0.0	---	---	---
2007	0	0	0	0	29,430,864	7,156,154,266	0.0	---	---	---
2008	0	0	0	0	50,837,296	11,937,666,661	0.0	---	---	---
2009	0	0	0	0	50,758,836	14,717,713,662	0.0	---	---	---
2010	0	0	0	0	48,741,181	14,183,830,622	0.0	---	---	---
2011	0	0	0	0	47,996,923	13,789,654,366	0.0	---	---	---
2012	48	48	104	3,249	29,087,357	5,453,221,165	0.2	67.7	2.2	31.2
<b>Felbamate</b>										
2004	55	56	182	6,508	19,649,466	4,366,868,224	0.3	118.3	3.3	35.8
2005	84	85	365	13,162	21,617,756	6,239,081,911	0.4	156.7	4.3	36.1
2006	97	101	434	14,735	23,282,609	6,547,596,060	0.4	151.9	4.5	34.0
2007	117	119	509	17,257	29,430,162	7,155,982,957	0.4	147.5	4.4	33.9
2008	184	185	728	24,709	50,836,243	11,937,359,633	0.4	134.3	4.0	33.9
2009	170	171	718	24,340	50,757,917	14,717,380,852	0.3	143.2	4.2	33.9
2010	171	173	726	25,349	48,740,292	14,183,517,029	0.4	148.2	4.2	34.9
2011	153	155	597	20,428	47,996,027	13,789,348,594	0.3	133.5	3.9	34.2
2012	60	61	184	6,624	29,086,679	5,453,093,827	0.2	110.4	3.1	36.0
<b>Gabapentin</b>										
2004	90,082	91,084	236,393	7,694,248	19,548,388	4,323,238,595	460.8	85.4	2.6	32.5
2005	118,071	119,762	296,280	9,993,502	21,516,936	6,182,063,919	548.7	84.6	2.5	33.7
2006	120,596	122,316	282,265	10,168,938	23,181,874	6,495,291,562	520.2	84.3	2.3	36.0
2007	162,923	165,451	375,815	13,607,272	29,141,721	7,086,962,467	559.1	83.5	2.3	36.2
2008	347,660	352,309	843,654	28,498,763	50,502,978	11,780,217,386	688.4	82.0	2.4	33.8
2009	425,965	433,008	1,054,534	36,214,837	50,446,724	14,535,026,803	844.4	85.0	2.5	34.3
2010	430,448	437,869	1,071,392	37,623,612	48,398,455	13,990,423,223	889.4	87.4	2.5	35.1
2011	425,589	432,255	1,024,713	37,168,858	47,601,068	13,579,988,691	894.1	87.3	2.4	36.3
2012	232,432	232,966	453,573	16,721,988	28,694,414	5,345,288,330	810.0	71.9	2.0	36.9

Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lacosamide</b>										
2004	0	0	0	0	19,649,857	4,366,981,987	0.0	---	---	---
2005	0	0	0	0	21,618,167	6,239,234,307	0.0	---	---	---
2006	0	0	0	0	23,283,011	6,547,744,271	0.0	---	---	---
2007	0	0	0	0	29,430,864	7,156,154,266	0.0	---	---	---
2008	0	0	0	0	50,837,296	11,937,666,661	0.0	---	---	---
2009	2,169	2,169	6,674	207,249	50,758,729	14,717,485,647	4.3	95.6	3.1	31.1
2010	3,507	3,524	13,950	444,502	48,739,571	14,182,740,537	7.2	126.7	4.0	31.9
2011	3,467	3,479	13,278	420,030	47,993,435	13,787,964,649	7.2	121.2	3.8	31.6
2012	1,555	1,556	4,689	149,892	29,083,705	5,452,359,285	5.3	96.4	3.0	32.0
<b>Lamotrigine</b>										
2004	16,901	16,991	59,247	1,948,486	19,628,116	4,359,293,092	86.1	115.3	3.5	32.9
2005	25,763	25,948	94,324	3,130,889	21,588,722	6,225,380,311	119.3	121.5	3.7	33.2
2006	30,513	30,747	107,981	3,739,936	23,244,039	6,531,021,251	131.3	122.6	3.5	34.6
2007	37,741	38,089	134,873	4,660,057	29,353,522	7,133,220,798	128.6	123.5	3.6	34.6
2008	66,016	66,523	228,229	7,518,694	50,695,158	11,891,328,450	130.2	113.9	3.5	32.9
2009	73,675	74,350	265,721	8,924,266	50,616,823	14,659,808,492	145.6	121.1	3.6	33.6
2010	69,582	70,308	250,440	8,602,740	48,599,190	14,126,802,213	143.2	123.6	3.6	34.4
2011	62,922	63,516	213,774	7,440,359	47,850,468	13,732,570,160	131.5	118.2	3.4	34.8
2012	28,448	28,493	76,510	2,705,856	28,978,144	5,428,445,100	98.2	95.1	2.7	35.4
<b>Levetiracetam</b>										
2004	7,329	7,380	24,090	786,236	19,641,088	4,363,472,512	37.3	107.3	3.3	32.6
2005	9,560	9,648	32,348	1,066,806	21,607,346	6,233,902,204	44.2	111.6	3.4	33.0
2006	10,677	10,770	36,316	1,234,700	23,269,737	6,542,001,777	45.9	115.6	3.4	34.0
2007	15,056	15,184	50,618	1,728,624	29,396,467	7,147,831,655	51.2	114.8	3.4	34.2
2008	31,339	31,552	105,224	3,408,162	50,784,324	11,918,848,341	61.7	108.8	3.4	32.4
2009	39,263	39,607	138,315	4,619,752	50,705,920	14,694,171,225	77.4	117.7	3.5	33.4
2010	38,784	39,127	132,517	4,515,895	48,682,005	14,158,554,174	79.7	116.4	3.4	34.1
2011	38,809	39,138	125,741	4,403,375	47,927,690	13,761,652,987	81.0	113.5	3.2	35.0
2012	20,016	20,045	50,513	1,780,278	29,027,460	5,439,561,776	69.0	88.9	2.5	35.2

**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lorazepam</b>										
2004	163,216	165,521	309,317	5,907,340	19,528,429	4,309,832,778	835.8	36.2	1.9	19.1
2005	230,508	235,912	439,633	8,289,077	21,496,606	6,157,833,995	1,072.3	36.0	1.9	18.9
2006	229,626	235,006	414,081	7,828,300	23,177,843	6,472,557,947	990.7	34.1	1.8	18.9
2007	281,122	288,091	566,892	11,674,067	29,228,160	7,067,106,297	961.8	41.5	2.0	20.6
2008	448,499	457,218	825,153	16,356,684	50,548,577	11,781,359,413	887.3	36.5	1.8	19.8
2009	534,594	547,846	1,008,566	20,178,751	50,487,004	14,529,074,738	1,058.9	37.7	1.9	20.0
2010	522,671	535,819	987,077	20,101,826	48,471,873	14,000,149,071	1,078.3	38.5	1.9	20.4
2011	456,878	467,023	823,081	16,959,936	47,739,316	13,614,121,890	957.0	37.1	1.8	20.6
2012	220,857	221,859	339,791	6,739,121	28,877,382	5,377,092,217	764.8	30.5	1.5	19.8
<b>Mephenytoin</b>										
2004	0	0	0	0	19,649,857	4,366,981,987	0.0	---	---	---
2005	1	1	1	30	21,618,167	6,239,234,124	0.0	30.0	1.0	30.0
2006	0	0	0	0	23,283,011	6,547,744,271	0.0	---	---	---
2007	0	0	0	0	29,430,864	7,156,154,266	0.0	---	---	---
2008	0	0	0	0	50,837,296	11,937,666,661	0.0	---	---	---
2009	0	0	0	0	50,758,836	14,717,713,662	0.0	---	---	---
2010	0	0	0	0	48,741,181	14,183,830,622	0.0	---	---	---
2011	0	0	0	0	47,996,923	13,789,654,366	0.0	---	---	---
2012	0	0	0	0	29,087,363	5,453,223,714	0.0	---	---	---
<b>Oxcarbazepine</b>										
2004	15,741	15,837	51,571	1,525,148	19,633,684	4,359,657,401	80.2	96.9	3.3	29.6
2005	16,231	16,369	52,367	1,625,719	21,600,503	6,229,733,955	75.1	100.2	3.2	31.0
2006	13,201	13,328	40,998	1,329,682	23,266,748	6,540,008,168	56.7	100.7	3.1	32.4
2007	13,238	13,386	42,202	1,379,602	29,402,172	7,147,661,470	45.0	104.2	3.2	32.7
2008	21,805	21,988	68,350	2,187,689	50,794,982	11,922,628,970	42.9	100.3	3.1	32.0
2009	24,050	24,292	75,400	2,464,933	50,721,751	14,701,042,340	47.4	102.5	3.1	32.7
2010	22,961	23,206	70,504	2,345,652	48,705,891	14,168,134,992	47.1	102.2	3.1	33.3
2011	20,271	20,481	59,527	1,997,301	47,961,678	13,774,427,844	42.3	98.5	2.9	33.6
2012	8,622	8,632	19,891	687,727	29,061,687	5,447,088,637	29.7	79.8	2.3	34.6

Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Phenobarbital</i></b>										
2004	3,786	3,841	9,774	302,565	19,638,242	4,363,143,036	19.3	79.9	2.6	31.0
2005	4,115	4,179	9,667	297,937	21,606,661	6,234,784,627	19.0	72.4	2.3	30.8
2006	4,007	4,065	7,937	243,626	23,274,178	6,544,228,367	17.2	60.8	2.0	30.7
2007	4,776	4,856	12,025	381,800	29,418,205	7,152,534,839	16.2	79.9	2.5	31.8
2008	6,350	6,479	14,301	444,665	50,820,554	11,932,071,516	12.5	70.0	2.3	31.1
2009	6,615	6,694	14,996	474,504	50,744,163	14,711,733,411	13.0	71.7	2.3	31.6
2010	5,805	5,909	12,843	400,494	48,728,181	14,178,617,638	11.9	69.0	2.2	31.2
2011	5,352	5,421	11,282	373,292	47,985,482	13,785,016,378	11.2	69.7	2.1	33.1
2012	2,560	2,563	4,321	135,669	29,079,020	5,451,248,770	8.8	53.0	1.7	31.4
<b><i>Phenytoin, phenytoin sodium</i></b>										
2004	12,494	12,661	39,666	1,390,745	19,608,359	4,353,335,209	63.7	111.3	3.2	35.1
2005	14,093	14,294	41,841	1,470,528	21,577,152	6,223,158,557	65.3	104.3	3.0	35.1
2006	13,236	13,436	39,193	1,426,728	23,246,217	6,534,162,946	56.9	107.8	3.0	36.4
2007	13,231	13,452	36,546	1,332,999	29,351,078	7,140,882,689	45.1	100.7	2.8	36.5
2008	22,534	22,798	67,443	2,293,911	50,747,262	11,907,859,800	44.4	101.8	3.0	34.0
2009	20,292	20,538	58,721	2,076,331	50,689,292	14,691,208,980	40.0	102.3	2.9	35.4
2010	16,689	16,941	48,313	1,783,546	48,680,169	14,160,962,171	34.3	106.9	2.9	36.9
2011	14,263	14,481	39,470	1,501,268	47,937,244	13,768,211,087	29.8	105.3	2.8	38.0
2012	6,550	6,564	14,396	559,603	29,040,022	5,443,448,798	22.6	85.4	2.2	38.9
<b><i>Pregabalin</i></b>										
2004	0	0	0	0	19,649,857	4,366,981,987	0.0	---	---	---
2005	8,990	8,990	14,497	411,246	21,617,921	6,238,810,791	41.6	45.7	1.6	28.4
2006	36,560	36,822	98,608	3,015,865	23,273,044	6,539,414,553	157.1	82.5	2.7	30.6
2007	52,715	53,135	126,153	3,937,889	29,332,689	7,139,853,596	179.7	74.7	2.4	31.2
2008	146,475	147,793	385,009	11,791,500	50,720,499	11,878,361,830	288.8	80.5	2.6	30.6
2009	94,603	95,589	241,118	7,808,372	50,665,549	14,664,641,723	186.7	82.5	2.5	32.4
2010	81,428	82,358	209,915	6,942,129	48,663,169	14,141,540,094	167.3	85.3	2.6	33.1
2011	69,017	69,672	166,977	5,647,857	47,921,578	13,751,804,421	144.0	81.8	2.4	33.8
2012	35,321	35,384	71,092	2,345,260	29,022,177	5,435,180,018	121.7	66.4	2.0	33.0

Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Primidone</b>										
2004	3,107	3,138	8,882	341,465	19,643,124	4,364,622,420	15.8	109.9	2.9	38.4
2005	3,659	3,724	10,199	396,362	21,611,140	6,236,146,770	16.9	108.3	2.8	38.9
2006	3,686	3,757	10,214	415,341	23,275,824	6,544,938,206	15.8	112.7	2.8	40.7
2007	4,682	4,791	12,451	514,737	29,410,497	7,152,450,886	15.9	109.9	2.7	41.3
2008	11,312	11,491	32,170	1,181,747	50,813,893	11,928,805,390	22.3	104.5	2.8	36.7
2009	11,634	11,851	33,670	1,285,645	50,738,820	14,708,636,836	22.9	110.5	2.9	38.2
2010	11,130	11,359	32,358	1,295,861	48,721,231	14,174,989,870	22.8	116.4	2.9	40.0
2011	11,039	11,204	30,872	1,285,517	47,975,608	13,780,432,087	23.0	116.5	2.8	41.6
2012	6,437	6,457	13,765	576,669	29,067,463	5,448,465,616	22.1	89.6	2.1	41.9
<b>Rufinamide</b>										
2004	0	0	0	0	19,649,857	4,366,981,987	0.0	---	---	---
2005	0	0	0	0	21,618,167	6,239,234,307	0.0	---	---	---
2006	0	0	0	0	23,283,011	6,547,744,271	0.0	---	---	---
2007	0	0	0	0	29,430,864	7,156,154,266	0.0	---	---	---
2008	0	0	0	0	50,837,296	11,937,666,661	0.0	---	---	---
2009	725	730	3,267	102,284	50,758,780	14,717,578,503	1.4	141.1	4.5	31.3
2010	410	412	1,984	62,368	48,740,742	14,183,604,944	0.8	152.1	4.8	31.4
2011	327	327	1,267	41,984	47,996,349	13,789,410,649	0.7	128.4	3.9	33.1
2012	94	94	267	9,112	29,086,955	5,453,136,739	0.3	96.9	2.8	34.1
<b>Tiagabine</b>										
2004	10,635	10,707	29,238	837,287	19,645,169	4,363,780,007	54.1	78.7	2.7	28.6
2005	5,077	5,109	12,697	376,694	21,613,600	6,235,940,163	23.5	74.2	2.5	29.7
2006	1,753	1,777	4,070	132,802	23,280,945	6,546,655,697	7.5	75.8	2.3	32.6
2007	1,200	1,211	2,864	91,825	29,427,821	7,155,333,417	4.1	76.5	2.4	32.1
2008	1,673	1,688	3,826	122,384	50,834,182	11,936,440,252	3.3	73.2	2.3	32.0
2009	1,239	1,244	2,827	94,072	50,756,856	14,716,756,077	2.4	75.9	2.3	33.3
2010	877	888	2,195	75,769	48,739,779	14,183,148,448	1.8	86.4	2.5	34.5
2011	521	528	1,135	38,170	47,995,747	13,789,150,978	1.1	73.3	2.2	33.6
2012	218	218	377	12,720	29,086,582	5,453,043,739	0.7	58.3	1.7	33.7



**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>										
2004	32,431	32,621	90,342	2,896,965	19,615,526	4,353,295,797	165.3	89.3	2.8	32.1
2005	44,705	45,160	131,275	4,263,919	21,580,986	6,217,940,577	207.1	95.4	2.9	32.5
2006	44,528	44,989	126,556	4,327,900	23,240,596	6,526,452,394	191.6	97.2	2.8	34.2
2007	51,098	51,701	144,710	5,039,350	29,353,612	7,130,459,165	174.1	98.6	2.8	34.8
2008	86,909	87,727	225,569	7,549,368	50,706,929	11,889,486,068	171.4	86.9	2.6	33.5
2009	111,517	112,956	312,161	10,546,959	50,639,838	14,658,622,766	220.2	94.6	2.8	33.8
2010	109,894	111,246	305,325	10,501,791	48,620,945	14,125,240,264	226.0	95.6	2.8	34.4
2011	94,978	96,071	245,191	8,633,445	47,874,980	13,731,905,627	198.4	90.9	2.6	35.2
2012	47,195	47,287	98,608	3,498,079	28,995,571	5,428,983,899	162.8	74.1	2.1	35.5
<b><i>Valproic acid</i></b>										
2004	1,813	1,835	4,268	207,307	19,648,628	4,366,350,106	9.2	114.3	2.4	48.6
2005	6,740	6,872	13,638	662,099	21,616,754	6,237,792,490	31.2	98.2	2.0	48.5
2006	4,483	4,528	9,996	414,627	23,280,791	6,545,982,096	19.3	92.5	2.2	41.5
2007	4,889	4,982	10,231	435,674	29,425,313	7,154,296,278	16.6	89.1	2.1	42.6
2008	7,375	7,533	18,882	879,535	50,831,242	11,934,337,643	14.5	119.3	2.6	46.6
2009	5,939	6,070	15,357	660,666	50,753,155	14,714,448,221	11.7	111.2	2.6	43.0
2010	4,214	4,276	10,432	420,595	48,735,478	14,180,987,472	8.6	99.8	2.5	40.3
2011	3,331	3,396	8,130	333,834	47,991,690	13,787,160,799	6.9	100.2	2.4	41.1
2012	1,464	1,465	2,818	112,876	29,082,995	5,452,107,521	5.0	77.1	1.9	40.1
<b><i>Vigabatrin</i></b>										
2004	0	0	0	0	19,649,857	4,366,981,987	0.0	---	---	---
2005	0	0	0	0	21,618,167	6,239,234,307	0.0	---	---	---
2006	0	0	0	0	23,283,011	6,547,744,271	0.0	---	---	---
2007	0	0	0	0	29,430,864	7,156,154,266	0.0	---	---	---
2008	0	0	0	0	50,837,296	11,937,666,661	0.0	---	---	---
2009	61	61	112	3,380	50,758,833	14,717,710,798	0.1	55.4	1.8	30.2
2010	148	149	841	25,989	48,741,118	14,183,783,746	0.3	175.6	5.7	30.9
2011	86	86	349	10,569	47,996,763	13,789,587,733	0.2	122.9	4.1	30.3
2012	20	20	77	2,294	29,087,255	5,453,200,088	0.1	114.7	3.9	29.8

**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Zonisamide</b>										
2004	5,411	5,441	17,011	508,431	19,645,538	4,364,823,808	27.5	94.0	3.1	29.9
2005	5,871	5,911	18,037	563,276	21,613,404	6,236,346,512	27.2	95.9	3.1	31.2
2006	4,271	4,307	12,901	416,899	23,278,723	6,545,508,579	18.3	97.6	3.0	32.3
2007	4,528	4,567	13,254	435,864	29,422,086	7,153,644,107	15.4	96.3	2.9	32.9
2008	8,268	8,330	22,747	737,475	50,823,974	11,932,706,045	16.3	89.2	2.8	32.4
2009	9,567	9,639	27,956	914,890	50,746,875	14,711,962,822	18.9	95.6	2.9	32.7
2010	8,895	8,971	26,479	887,259	48,729,868	14,178,490,492	18.3	99.7	3.0	33.5
2011	7,821	7,870	22,312	758,835	47,985,228	13,784,388,014	16.3	97.0	2.9	34.0
2012	3,400	3,403	7,736	271,098	29,078,541	5,451,026,865	11.7	79.7	2.3	35.0